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Abstract 
Defects in the proliferation, differentiation, and activity of bone marrow (BM)-
derived vasculogenic/vascular stem cells (VSCs) have been observed in diabetes 
and contribute to the development of vascular complications.  Diabetes leads to 
enhanced bone marrow adipogenesis, altering the composition of the BM stem cell 
(SC) niche and potentially disrupting the normal functioning of resident VSCs.   
Here, I establish that adipocytes have a negative influence on SC survival in culture.  
I also show that adipocytes and osteoblasts are responsible for the creation of 
distinct extracellular microenvironments, with unique expression patterns of several 
pro- and anti-angiogenic factors with known effects on VSCs, such as fibronectin, 
Notch ligands, stromal cell-derived factor-1, and angiopoietin-1 and -2.  I conclude 
that alterations in marrow composition may mediate the connection between 
hyperglycemia, VSC dysfunction, and impaired vascular repair in diabetes.  
 
Keywords:  diabetes, bone marrow, mesenchymal progenitor cells, adipogenesis, 
differentiation, vascular stem cells, endothelial progenitor cells, stem cell niche 
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Chapter 1 : Introduction1 
1 Introduction 
1.1 Diabetes 
 Diabetes mellitus is a chronic metabolic disease characterized by insufficient 
cellular responses to high blood glucose.  Type 1 diabetes, comprising 5-10% of all 
cases, is generally considered to be a disease of the young, with most patients 
diagnosed before the age of twenty1, 2.  This disorder is characterized by autoimmune 
destruction of the pancreatic β-cells responsible for the production of insulin in response 
to glycemic load1, 2.  Destruction of β-cells results in an absolute insulin deficiency and 
high blood glucose levels.  The cause of type 1 diabetes is considered to be polygenic 
and multifactorial2.  Type 2 diabetes, also known as noninsulin-dependent diabetes 
mellitus, comprises the bulk of the instances of the disorder and involves a relative lack 
of insulin signalling stemming from peripheral insulin resistance and β-cell dysfunction1, 
3.  In this form, hyperglycemia develops slowly over the course of several years1.  
During this asymptomatic period, hyperinsulinemia may occur as the β-cells of the 
pancreas struggle to keep up with the ever-increasing insulin resistance of target 
tissues, allowing for inappropriate hepatic gluconeogenesis1, 3.  Beta-cell function begins 
                                                 
 
1
 Portions of this chapter have been adapted from: Piccinin MA, Khan ZA.  Pathophysiological role of 
enhanced bone marrow adipogenesis in diabetic complications.  Adipocyte 2014; 3:4.  Reproduction of 
portions of this article is at the permission of Taylor & Francis LLC.  
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to falter gradually over time, reducing insulin secretion and resulting in hyperglycemia4.  
A third form of the disease is gestational diabetes mellitus (GDM), which is initially 
diagnosed during pregnancy1, 5.  GDM is characterized by insulin resistance and a 
considerable reduction in β-cell function by late pregnancy5, 6.  GDM affects 
approximately 14% of pregnancies, and although the majority of cases resolve post-
partum, those affected have a 65% chance of developing type 2 diabetes in the five 
years following delivery1, 5-7. 
1.1.1 Epidemiology  
 Diabetes is an incredibly prevalent disease, afflicting an estimated 347 million 
individuals worldwide as of 20088. In the United States alone, there are approximately 
20.9 million diabetes sufferers, with a prevalence of 6.9% in men and 5.9% in women9. 
These prevalence estimates have increased sharply since 1980, by 156% in men and 
103% in women, and is predicted to continue rising, even while holding the current 
levels of obesity constant9, 10. If existing trends persist, one in three U.S. adults is 
anticipated to have diabetes by 205011. Diabetes was responsible for 5.1 million deaths 
globally in 2013, with one person dying of the disease every six seconds12. The disease 
is anticipated to become the fifth leading cause of mortality worldwide by the year 2030, 
underlying 3.5% of all deaths13. This disease represents a massive burden on the global 
economy through significant reductions in productivity and the 2.3-fold increase in the 
utilization of health care resources by diabetics14. Twelve percent of worldwide health 
care expenditure is related to the care of diabetes, including $548 billion spent in the 
United States in 2013, primarily due to the management of diabetic sequelae12, 15, 16.   
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1.1.2 Diabetic Vascular Complications 
 In developed countries, the morbidity associated with diabetes is primarily 
associated with secondary sequelae rather than the acute complications, such as 
ketoacidosis and diabetic coma, which are pervasive in low- and middle-income 
nations17.  An estimated 72% of diabetics suffer from at least one long-term vascular 
complication of the disease16.  Vascular complications can broadly be divided into two 
categories on the basis of the size of the blood vessel affected.  Microvascular sequelae 
include retinopathy, neuropathy, cardiomyopathy, and nephropathy, while peripheral 
vascular disease and coronary artery disease are common macrovascular 
complications16.  These complications are the consequence of hyperglycemia-induced 
damage to blood vessels and aberrant vascular repair mechanisms.   
1.1.2.1 Mechanisms of Diabetic Vascular Complications 
 The endothelial cells (ECs) comprising the tunica intima, the innermost layer of 
the vasculature, are the first cells in the body to encounter chronically elevated blood 
glucose levels in diabetes.  The most abundant glucose transporter isoform expressed 
by ECs is glucose transporter 1 (GLUT1), which aids in the facilitated diffusion of 
glucose across the plasma membrane18-20.  The expression and function of GLUT1 is 
non-responsive to changes in glucose or insulin concentration, resulting in increased 
glucose uptake under hyperglycemic conditions and heightened intracellular glucose 
levels20-23.  The cytosolic glucose is then processed via glycolysis and the tricarboxylic 
acid (TCA) cycle to generate electron donors nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2) for use in the mitochondrial electron transport 
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system and provide energy to pump protons across the mitochondrial membrane22.  A 
transmembrane voltage gradient is then established, which can be harnessed to drive 
production of adenosine-5’-triphosphate (ATP)22.  With excess glucose being processed 
through the TCA cycle in hyperglycemic conditions, an increased number of electrons 
are transferred into the electron transport chain, raising trans-membrane 
hyperpolarization until a threshold limit is reached22.  Electron movement is then halted 
at complex III, resulting in an accumulation of electrons at coenzyme Q22.  Coenzyme Q 
dissipates this excess charge through the partial reduction of molecular oxygen to form 
the free radical superoxide anion22.   
 Superoxide is able to exert its detrimental effects on the vasculature through a 
number of mechanisms.  The superoxide anion is able to inactivate nitric oxide (NO) by 
converting the potent vasodilator into peroxynitrite24, 25.  Peroxynitrite acts as an 
oxidizing agent, reacting with tetrahydrobiopterin (BH4) which serves as a requisite 
cofactor for endothelial nitric oxide synthase (eNOS)26.  This results in uncoupling of 
eNOS, favoring the generation of superoxide over NO production and leading to an 
accumulative increase in reactive oxygen species (ROS) and runaway inhibition of NO 
bioactivity27, 28. 
This overactive production of ROS, both directly from the electron transport chain 
and indirectly through uncoupled eNOS activity, leads to the induction of four 
mechanisms which stimulate primary biochemical changes within ECs: 1) increased 
activity of the polyol pathway, 2) generation of advanced glycation end-products 
(AGEs), 3) activation of protein kinase C (PKC), and 4) stimulation of the hexosamine 
pathway (reviewed in detail in Brownlee 2005)22.  The activation of these pathways 
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leads to endothelial dysfunction through further induction of ROS production, the 
release of inflammatory cytokines, increased synthesis of extracellular matrix 
components, diminished EC migration and proliferation, and endothelial apoptosis 
(Figure 1.1)22, 29-37.  
In addition to diminishing the production of NO, hyperglycemia and 
hyperinsulinemia further potentiate the vasoactive effects of diabetes by stimulating the 
production and activation of the most powerful known endogenous vasoconstrictor, 
endothelin-138-40.  Hyperglycemia appears to enhance endothelin-1 activity through the 
increased activation of PKC-β and –δ, while insulin likely exerts its effect via the tyrosine 
kinase activity of the insulin receptor (IR)38-40.  Interactions between endothelin-1 and its 
receptors on vascular smooth muscle cells results in the release of Ca2+ from 
intracellular stores and the opening on non-specific cation channels41.  This leads to 
depolarization sufficient to activate L-type Ca2+ channels and induce perivascular cell 
contraction and vasoconstriction41, 42.  Increased levels of endothelin-1 mRNA and 
peptide have been observed in several organs known to be susceptible to diabetic 
complications, such as the heart, kidneys, and retina38, 43-45.  The dual vasoactive 
effects of hyperglycemia on NO and endothelin-1 lead to diminished endothelial 
integrity, culminating in impaired perfusion of targeted tissue and ischemia46, 47. 
In the healthy patient, vascular repair mechanisms would be employed to restore 
the damaged blood vessels and preserve the function and circulation of affected tissues 
(Figure 1.2 A)46.  Revascularization may occur through the proliferation and migration of 
mature ECs adjacent to injured regions or through the chemokine-guided recruitment of   
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Figure 1.1.  Mechanisms of hyperglycemia-induced endothelial damage in 
diabetes. 
Glucose enters and accumulates in ECs via Glut1, which is non-responsive to changes 
in glucose concentration.  Disproportionate glucose metabolism overwhelms the 
electron transport chain, causing an accumulation of electrons at coenzyme Q.  This 
excessive charge is then dissipated through the partial reduction of molecular oxygen 
into the free radical superoxide.  Superoxide promotes the conversion of the potent 
vasodilator NO into inactive peroxynitrite and uncoupling of eNOS, leading to a loss of 
vasoregulation.  Superoxide also stimulates the generation of other ROS, which by 
several distinct mechanisms, mediate EC dysfunction and survival. 
[AGE = advanced glycation end product; EC = endothelial cell; FADH2 = flavin adenine 
dinucleotide; NADH = nicotinamide adenine dinucleotide; NO = nitric oxide; PKC = 
protein kinase C; Q = coenzyme Q; ROS = reactive oxygen species]  
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Figure 1.2.  Impaired vascular repair in diabetes. 
(A) In healthy individuals, endothelial injury would signal for the mobilization of stem 
cells from the BM into circulation and contribute to vascular regeneration.  Injury may 
cause some vascular stem cells to produce lineage-restricted EPCs which home to the 
site of injury and repair damaged vasculature, though the identity of these cells is not 
fully clear.  (B) In diabetics, this response to endothelial damage is disrupted, through a 
combination of reduced VSCs in the marrow and impaired EPC migration and 
vasculogenic function. 
[BM = bone marrow; EPC = endothelial progenitor cell; VSC = vascular stem cell] 
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bone marrow (BM)-derived endothelial progenitor cells (EPCs) to the site of injury48-50.  
This response is disrupted and occurs unevenly in type 1 diabetics with poor glycemic 
control and nearly all type 2 diabetic subjects (Figure 1.2 B)51.  The non-uniform 
distribution of vascular repair leads to divergent, tissue-specific complications, with 
heightened retinal and renal vessel formation and a lack of revascularization in the 
lower limbs and heart52-56.  These pathological changes may be partially resultant from 
deficits in EPC development, proliferation, migration, and/or function.  Analyses of EPCs 
from most diabetic subjects reveal a reduced number in both the circulation and the 
bone marrow, as well as impaired proliferation, mobilization, and capacity for vessel 
formation56-66.  The mechanisms underlying these cellular changes have not yet been 
fully elucidated, but may relate to the diabetes-induced alterations to the BM 
microenvironment from which EPCs originate. 
1.2 Stem Cells in the Bone Marrow 
The primary role of the BM is to support the maintenance and differentiation of 
hematopoietic stem cells (HSCs).  In addition to blood cell precursors, the marrow is 
also an abundant source of other precursors including mesenchymal and vascular cells.  
Each of these progenitor cell classes reside within a hierarchy of progressively more 
differentiated cell types (Figure 1.3).  HSCs are responsible for the formation of novel 
blood cells, generating leukocytes, erythrocytes, and thrombocytes.  Mesenchymal 
precursors regulate the creation of the marrow stroma that supports the HSC 
population, while vascular stem cells (VSCs) serve as a pool of progenitors for blood 
vessel formation. 
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Figure 1.3.  Developmental origin and potential of marrow-resident SCs. 
Hypothesized model of stem cell hierarchy in the marrow showing mesodermal SCs 
giving rise to embryonic hemangioblasts and mesenchymal progenitor cells (MPCs, also 
known as mesenchymal stem/stromal cells (MSCs)).  In the developing embryo, 
hemangioblasts serve as precursors for hematopoietic and vascular lineages, though 
the postnatal existence of hemangioblasts is disputed.  MPCs have a tri-lineage 
differentiation potential and able to develop into adipocytes, osteoblasts, and 
chondrocytes. 
[EC = endothelial cell; EPC = endothelial progenitor cell; HSC = hematopoietic stem 
cell; MPC = mesenchymal progenitor cell; SC = stem cell; SMC = smooth muscle cell; 
VSC = vascular stem cell]  
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1.2.1 Mesenchymal Precursors 
The first description of mesenchymal precursors in the BM came from 
Friedenstein, Chailakhjan, and Lalykina in 1968, who observed a monolayer of colony-
forming fibroblastic cells developing from guinea pig marrow aspirates67.  These 
mesenchymal precursors are possibly the most abundant precursor type in the marrow 
yet their identity and true differentiation potential is obscure and controversial.  These 
cells are often referred to as marrow/mesenchymal stem/stromal cells (MSCs) in the 
literature.  I have elected to refer to these cells as mesenchymal precursor/progenitor 
cells (MPCs) due to the lack of experimental evidence for the ‘stem’ cell phenotype and 
hematopoietic differentiation ability.  Furthermore, stromal cell definition may also be 
misleading depending on the context.  For example, a well-known function of these 
mesenchymal precursors is tissue repair following injury and thus, not solely a 
supportive framework for other functional cell types within the BM.  Therefore, I believe 
a proper term for these cells is mesenchymal progenitor/precursor cell.   
MPCs have typically been isolated from the BM mononuclear cell fraction on the 
basis of their adherence to plastic surfaces relative to hematopoietic cells, although this 
imprecise method invariably results in a contaminated heterogeneic cell population68-70.  
As the characterization of MPCs improved and selective surface markers were 
identified, monoclonal antibodies such as Stro-1 have been employed in order to better 
isolate a homogenous subset of cells for experimentation and analysis68, 69.  Other 
surface antigens of mesenchymal precursors include CD73, CD90, and CD105, though 
the cells must be devoid from the expression of CD11b, CD14, CD19, CD34, CD45, and 
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CD79α in order to exclude cells with a hematopoietic phenotype71, 72.  Additionally, the 
cells must be capable of in vitro differentiation into osteoblasts, adipocytes, and 
chondroblasts (Figure 1.4), though in vivo, chondrogenesis is typically localized to the 
osteochondral environment of joint cavities as opposed to our primary area of interest, 
the BM71, 73, 74.  
1.2.1.1 Osteoblastogenesis & Chondrogenesis 
 The predominant factor involved in regulating osteoblastic differentiation is Runt-
related transcription factor 2 (Runx2; also known as core-binding factor subunit α 1 
(CBFα1)75.  Once induced by bone morphogenic protein-7 (BMP7), Runx2 and its 
heterodimeric subunit CBFβ bind the Runx consensus sequence present in the 
promoter regions of key osteoblastic genes, leading to the development of MPCs into 
osteochondro-progenitor cells76-78.  Runx2-induced expression of the transcription factor 
Sp7 (also known as osterix) guides these bi-potential cells towards the osteoblastic 
lineage, while repressing Sex determining region-Y box 9 (Sox9) that directs 
chondrogenic development77, 79.  Together, Runx2 and Sp7 drive the expression of the 
major osteoblastic genes that contribute to the bone cell phenotype, including bone 
gamma-carboxyglutamic acid-containing protein (BGLAP; also known as osteocalcin), 
collagen 1A1, and osteopontin76, 80.  Additionally, Runx2 also plays a major role in 
suppressing the cell division of differentiating progenitor cells, entering osteoblasts into 
a post-proliferative state81.   
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Figure 1.4.  Key transcription factors regulating MPC differentiation. 
MPCs differentiate into adipocytes upon induction of PPARγ and the C/EBP family of 
transcription factors.  Activation of Runx2 stimulates MPC commitment to osteoblastic 
or chondrogenic lineages.  Subsequent expression of Sox9 directs differentiation 
towards chondrocytes, while Sp7 inhibits this pathway to facilitate osteoblastogenesis. 
[C/EBP = CCAAT-enhancer-binding protein; MPC = mesenchymal progenitor cell; 
PPARγ = peroxisome proliferator-activated receptor γ; Sox9 = sex determining region 
Y-box 9] 
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1.2.1.2 Adipogenesis 
 Adipogenic differentiation of MPCs is a biphasic process, broadly divided into two 
stages: determination and terminal differentiation.  In culture, the process requires 
approximately seven days from the initiation of adipogenic stimulation and is tightly 
regulated by an intricate cascade of transcription factors and ligand-receptor 
interactions82.   
1.2.1.2.1 Adipogenic Determination 
 Determination involves commitment of precursor cells to development along the 
adipogenic lineage as a pre-adipocyte (Figure 1.5A).  At this stage, pre-adipocytes 
remain morphologically identical to their precursor, although these cells have lost the 
ability to differentiate along any other developmental pathway82, 83.  The molecular 
mechanisms and interactions underlying adipogenic commitment are not well 
understood.  BMP4 is believed to play an important role in determination, having 
repeatedly been shown capable of committing murine C3H10T1/2 cells to adipocyte 
development84-87.  Hypomethylation of the BMP4 locus is suspected to be involved, as 
treatment with 5-azacytidine, a potent DNA methyltransferase inhibitor, is able to induce 
commitment of precursor cells to the adipogenic lineage by increasing the accessibility 
of the BMP4 transcriptional start site88, 89.  Interactions between BMP4 and its cell 
surface receptor BMP4R1A result in the rapid phosphorylation of Smad1/5/8, which 
complexes with Smad486.  This protein complex undergoes nuclear translocation, where 
it controls gene expression, though the specific targets are not yet known86, 90.  In many   
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Figure 1.5.  Schematic illustrating adipogenic determination and terminal 
differentiation. 
Differentiation of MPCs into adipocytes is governed by a tightly-regulated transcriptional 
cascade.  (A) The first stage of adipogenesis involves commitment of MPCs to the 
adipogenic lineage in a process known as determination.  Determination is primarily 
regulated by a BMP and Smad signalling pathway.  (B) Terminal differentiation of 
committed preadipocytes into mature adipocytes begins with C/EBP-β and C/EBP-δ 
inducing the transcription of PPARγ and C/EBPα, which are then able to facilitate the 
transcription of genes responsible for producing the adipocytic phenotype. 
[BMP4 = bone morphogenic protein 4; BMP4R1A = bone morphogenic protein 4 
receptor 1A; C/EBP = CCAAT-enhancer-binding protein; ERK = extracellular signal-
regilated kinase; FABP4 = fatty acid binding protein 4; Glut4 = glucose transporter 4; IR 
= insulin receptor; LPL = lipoprotein lipase; MEK = mitogen-activated protein kinase 
kinase; MPC = mesenchymal progenitor cell; PPARγ = peroxisome proliferator-
activated receptor γ] 
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well-studied murine pre-adipocyte cell lines, determination and terminal differentiation 
are separated by a brief period of proliferation, known as mitotic clonal expansion, 
though it has previously been demonstrated that this stage is not a requirement for 
human BM-MPC development91, 92.   
1.2.1.2.3 Terminal Differentiation 
  The terminal differentiation of committed progenitor cells into mature adipocytes   
is largely controlled by peroxisome proliferator-activated receptor-γ (PPARγ), which is 
known as ‘the master regulator of adipogenesis’, and the CCAAT-enhancer-binding 
protein (C/EBP) family of transcription factors.  Pro-adipogenic stimuli promote the 
hyper-phosphorylation and activation of C/EBP-β by mitogen-activated protein kinase 
kinase (MEK)/extracellular signal-regulated kinase (ERK) signalling93, 94.  C/EBP-β acts 
synergistically with C/EBP-δ to enhance the expression of PPARγ and C/EBP-α through 
direct binding to potential C/EBP sites located within the PPARγ and C/EBP-α promoter 
regions83, 95.  PPARγ and C/EBP-α form a positive feedback loop, in which each factor 
is capable of promoting the expression of the other in order to maintain the 
differentiated state96, 97.  C/EBP-α is also able to bind its own C/EBP-regulatory element 
to reinforce its own expression independently of PPARγ-mediated regulation98.  PPARγ, 
in tandem with its heterodimeric partner retinoid X receptor (RXR), and C/EBP-α act in 
concert to stimulate the expression of a number of adipocyte-specific genes, including 
fatty acid binding protein-4 (FABP4), Glut4, lipoprotein lipase, glycerophosphate 
dehydrogenase, and acetyl CoA carboxylase, among others (Figure 1.5B)97.  C/EBP-α 
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also becomes phosphorylated by cyclin D3, resulting in the formation of growth-
inhibitory complexes in order to enter adipocytes into a non-proliferative state99. 
1.2.2 Vascular Stem Cells  
VSCs are defined as “self-renewing multipotent stem cell[s] that [give] rise to 
vascular lineages”100.  VSCs, which may also be known as angioblasts, share a 
common developmental origin with HSCs as hemangioblasts residing within embryonic 
blood islands, though some evidence suggests that hemangioblasts may persist into 
adulthood in small numbers within the BM101-103.  The development of a hemangioblast 
into either a VSC or an HSC is contingent on the expression of vascular endothelial 
growth factor (VEGF) receptor-2 (VEGFR-2; also commonly known as fetal liver kinase-
1 or Flk-1) and the stem cell leukemia (SCL) transcription factor, respectively104, 105.  
SCL appears to be the predominant director of hemangioblast development and 
hematopoietic fate via Runx1 signalling, while VEGFR-2 is necessary for vascular 
lineage progression104-107.  Hemangioblasts have been characterized by the expression 
of VEGFR-2 and SCL, along with CD133 (a stem and progenitor cell marker; also 
known as AC133 or prominin-1) and CD34 (a cell adhesion factor mediating stem cell 
(SC) attachment to the BM)101, 103.  Stimulation of VSCs with VEGF induces their 
development into lineage-restricted EPCs, which can then enter into circulation, 
differentiate into mature ECs, and contribute to the formation or repair of the 
arteriovenous network108, 109. 
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1.2.2.1 Endothelial Progenitor Cells 
 EPCs are committed progenitor cells that will eventually give rise to the ECs that 
participate in the repair of damaged vasculature110.  BM-derived EPCs enter into 
circulation and migrate to the site of vascular injury, where they restore impaired blood 
flow111, 112.  Vessel repair may be comprised of angiogenesis and vasculogenesis.  In 
angiogenesis, blood vessels are formed by sprouting or intussusception (splitting) of 
pre-existing vascular networks113.  Vasculogenesis denotes the de novo formation of 
blood vessels from precursor cells.  In the embryo, vasculogenesis is employed in the 
formation of the earliest vascular plexus, after which angiogenesis was originally 
believed to take over as the predominant mechanism of vessel formation113-115.  Only 
relatively recently has vasculogenesis been accepted as a complementary method of 
postnatal neovascularization, with circulating EPCs now serving as a novel biomarker 
for vascular health116-120.   
 Asahara and colleagues were the first to identify and isolate EPCs from adult 
circulation in 1997121.  EPCs were obtained through magnetic bead selection for CD34-
positive cells in the leukocyte fraction of peripheral blood.  After seven days of culture, 
these progenitor cells adopted an endothelial-like phenotype and gene expression 
pattern.  Labelled CD34-positive cells were then injected into an athymic mouse model 
of hind limb ischemia to evaluate vasculogenic capacity.  After 6 weeks, there was 
significant incorporation of CD34-positive cells into capillaries of the ischemic limb 
relative to an injection of control CD34-depleted cells, suggesting a great potential of 
these cells to contribute to neovascularization.  Following this initial discovery of EPCs 
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in postnatal circulation, these cells have since been shown to significantly contribute to 
vessel formation in both physiological and pathological capacities46, 49, 122, 123.   
EPCs that have entered into circulation can be obtained through culture of 
peripheral blood mononuclear cells in a VEGF-containing medium108, 124.  
Characterizing EPCs has proven difficult, largely due to the co-occurrence of mature 
circulating ECs, likely shed from the vessel walls, within peripheral circulation46.  
Additionally, there appear to be two distinct categories of EPCs that are able to 
contribute to blood vessel repair and development125.  These two cell types can be 
distinguished primarily on the basis of their morphology and ability to proliferate124, 126.  
Early-outgrowth EPCs are spindle-shaped CD14- and CD45-positive cells that appear 
after about 10-14 days of culture and exhibit a low propensity for mitogenesis125-131.  
This population is believed to arise from the reprogramming of myeloid progenitors or 
monocytes into cells with an endothelial-like phenotype130-134.  Also contained within the 
peripheral blood mononuclear fraction is a small subset of cobblestone-shaped, highly 
proliferative cells, known as late-outgrowth colonies or endothelial colony-forming cells 
that appear after three or more weeks of culture126, 128, 129, 135-137.  Late-outgrowth cells 
are free from monocytic and hematopoietic markers and correspond to BM-derived 
EPCs138.  Both early- and late-outgrowth cell types appear to have a similar capacity for 
angiogenesis in vivo, though early EPCs were shown to be incapable of forming the 
capillary-like structures characteristic of vasculogenesis126, 129, 139, 140.  From this point 
forward, discussion of EPCs will centralize solely on the BM-derived late-outgrowth EPC 
cell type. 
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 As an intermediate between SCs and mature ECs, EPCs express markers of 
both stem and fully differentiated cells141.  In the BM, VSC precursors able to give rise to 
EPCs are characterized by the expression of VEGFR-2, CD34, and CD133142-144.  
CD133 is the only one of these markers not expressed by mature endothelial cells, 
which allows EPCs or cells capable of giving rise to EPCs to be distinguished from the 
circulating EC population50, 115.  A single surface marker specific to EPCs has yet to be 
described, although CD133 is currently considered to be the putative marker for the 
identification of EPCs145-147.  Functional characteristics of EPCs include the ability to 
uptake acetylated low density lipoprotein and adhere to the fucose-binding lectin Ulex 
europaeus agglutinin-1, which are features also shared by mature ECs127, 135.  Upon 
activation, BM-EPCs enter peripheral circulation and increase their expression of 
endothelial markers, such as vascular endothelial-cadherin (VE-cadherin), von 
Willebrand factor (vWF), tyrosine kinse with immunoglobulin-like and EGF-like domains 
2 (Tie-2), eNOS, and CD31 (also known as platelet endothelial cell adhesion molecule-1 
or PECAM-1), and reduce expression of the SC marker CD133108, 113, 148.  Once fully 
differentiated and incorporated into the endothelium, the expression of CD133 is 
abolished148-150.  In culture, CD133 is lost upon adherence of cells to culture plates.  
While the expression of VEGFR-2 persists following maturation, CD34 may or may not 
be expressed by differentiated ECs depending on the size of the blood vessel113, 148. 
 Though the specific cellular and non-cellular interactions in the marrow that 
govern EPC derivation and release into circulation are poorly understood, a number of 
studies have unanimously reported that the proliferation, differentiation, and migration of 
EPCs are stimulated by tissue ischemia.  A lack of oxygen within a microenvironment 
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prevents the proteosomal degradation of heterodimeric hypoxia-inducible factor (HIF) 
within resident cells by a pair of mechanisms151.  Under normoxic conditions, 
hydroxylation of two prolyl residues of the HIF-α subunit facilitates the protein’s 
interaction with a ubiquitin ligase and targets the protein for destruction151-155.  
Additionally, a HIF-α carboxyl-terminal asparginyl residue may undergo β-hydroxylation 
in order to prevent the binding of the transcriptional co-activator p300151, 153, 156.  Both of 
these hydroxylation reactions require the use of molecular oxygen as a requisite 
cofactor157, 158.  Under ischemic conditions, the failings of these regulatory measures are 
unable to target HIF to the proteosome or prevent the transcriptional activity of the 
protein.  HIF can then up-regulate the expression and secretion of VEGF and 
stem/stromal cell-derived factor-1 (SDF-1), which are believed to serve as principal 
signalling molecules in EPC activation and mobilization, respectively159-165.  VEGF and 
SDF-1, along with other angiogenic factors such as insulin-like growth factor-2 (IGF-2), 
enhance the expression and activity of matrix metalloproteinase (MMP)-9 in the BM, 
which cleaves the membrane-bound Kit-ligand, known as stem cell factor (SCF) to 
release its soluble form166-168.  Soluble SCF interacts with its receptor, c-Kit, expressed 
by various stromal cells to augment the BM microenvironment in favor of SC 
proliferation and mobilization into circulation147, 166, 169.  Several signalling pathways 
have been implicated in directing the proliferation and migration of EPCs, including 
Sonic hedgehog (Shh) acting through phosphoinositide-3-kinase (PI3K) and protein 
kinase B (PKB)-mediated phosphorylation of NOS, as well as VEGF-induced signalling 
via a protein kinase D-1 (PKD-1)-histone deacetylase (HDAC) 7 axis170-172.  These 
signalling cascades result in an influx of EPCs from the BM into circulation, which use 
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an SDF-1- and/or IGF2-mediated chemotactic gradient in order to home to sites in need 
to neovascularization164, 168, 173-175.   
 In diabetes, the EPC-recruiting response to hyperglycemia-induced vascular 
injury appears to be impaired.  In cultured samples of peripheral blood obtained from 
type 1 diabetics, the number of EPCs in circulation was reduced by 44% relative to 
control subjects, suggesting that the disease impairs mobilization of precursor cells from 
the BM62.  The same study also found that the EPCs of diabetic patients exhibited a 
significantly diminished capacity for angiogenesis in an in vitro assay62.  Analysis of 
CD34-positive EPCs derived from type 1 diabetics showed reduced in vitro 
differentiation of the progenitors into mature ECs176.  Similar results demonstrating 
impaired differentiation, migration, and function have also been obtained through the 
study of type 2 diabetic and mixed diabetic  population EPCs, as well as animal 
models57-59, 61, 118, 177-182.  Additionally, our laboratory has shown that hyperglycemia 
significantly increases caspase-3 activity in EPCs183.  The number of EPCs in circulation 
has been identified as an important biomarker for vascular function and overall 
cardiovascular risk and thus, understanding the mechanisms underlying diabetic EPC 
dysfunction is crucial117-120.  Furthermore, the quantities of EPCs from subjects with 
long-duration type 1 diabetes free from vascular complications were equivalent to non-
diabetic controls and demonstrated an enhanced migratory ability184.  This finding 
suggests that preservation of the EPC population and its function are critical in 
preventing or ameliorating diabetic damage to the vasculature.   
 The underlying cause of the EPC dysfunction that occurs in diabetes is not 
presently known178.  A number of potential mechanisms have been suggested, including 
  
24 
impairment of circulating EPC survival under hyperglycemic conditions and a reduction 
in the hypoxia-induced expression of pro-angiogenic factors VEGF and SDF-1185-188.  I 
propose that a major contributor to this EPC dysfunction may be disrupted signalling 
resulting from diabetes-induced alterations to the BM SC niche. 
1.2.3 Stem Cell Niche 
As with other SCs, the fates of VSCs in vivo are governed by intracellular gene 
regulation, though this intrinsic program is subject to influence by external elements in 
order to maintain an appropriate balance between self-renewal and differentiation189.  
These extrinsic cues come from SCs’ interactions with the surrounding 
microenvironment.  This microenvironment is comprised of soluble paracrine signalling 
molecules, interactions with nearby stromal cells, and the extracellular matrix, which are 
collectively referred to as the SC niche189-191.  The specific composition of these niches 
are vital in regulating SC quiescence, self-renewal, and differentiation in nearly every 
progenitor cell type166, 191, 192.  The BM SC niche is comprised of a number of cell types, 
as well as their secretory products, cell-cell interactions, and extracellular matrix (ECM) 
(Figure 1.6).  A number of SC niches have been identified and well-characterized, 
including the epithelial, intestinal, and hematopoietic niches.  Recent work has 
broadened our understanding of the BM HSC niche, including changes to the niche in 
disease states such as diabetes and obesity193, 194.  Although EPC dysfunction is 
associated with the development of pathological vascular complications, comparatively 
little is known about the role of the diabetic BM SC niche in mediating this process. 
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Figure 1.6.  Schematic of interactions between BM SC niche components. 
Within the BM reside three SC types: HSCs, MSCs, and VSCs.  The self-renewal and 
differentiation of these SCs is controlled by the surrounding microenvironment, which 
includes MPCs, adipocytes, osteoblasts, and endothelial cells.   
[EPC = endothelial progenitor cell; HSC = hematopoietic stem cell; MSC = 
mesenchymal stem cell; SC = stem cell; VSC = vascular stem cell] 
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1.3 Bone and Marrow Complications of Diabetes 
One of the extravascular complications of diabetes involves changes to the 
composition and structural integrity of the skeletal system.  This phenomenon was first 
described by Morrison and Bogan in 1927, who observed impaired bone development 
and skeletal atrophy in children with long-standing diabetes195.  Clinically, it has been 
well-documented that diabetes induces a significant increase in fracture risk among 
both type 1 and type 2 diabetics, as described by a 2007 systematic review by 
Janghorbani et al. and a 2007 meta-analysis by Vestergaard196, 197.  These fractures are 
particularly common in the radius, femur, and hip and may partially be the result of an 
increased propensity for falls due to retinopathy and lower limb neuropathy198.   
 Interestingly, type 1 and type 2 diabetes have distinct effects on skeletal 
composition.  Type 1 diabetics suffer from a substantially increased risk of fragility 
fractures – approximately 6-fold higher than the general population – and as to be 
expected, display osteopenia and significant reductions in bone mineral density 
(BMD)196, 197, 199-203.  One study has reported the prevalence of osteoporosis (defined as 
BMD at least 2.5 standard deviations below the mean BMD of an average 30-year old 
white woman) as 19.1% among type 1 diabetics (with mean age of 30 years), with 
osteopenia (defined as BMD 1-2.5 standard deviations below the same standard) being 
found in 34-67% of patients201, 204-206.  Low BMD has also been found to correlate with 
an increased severity and incidence of chronic vascular complications, underscoring the 
interrelatedness between the BM and endothelial damage201, 203, 206.  As type 1 diabetes 
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typically presents during childhood or adolescence, low bone mass may be the result of 
impaired bone formation during critical skeletal growth periods195, 207.   
Type 2 diabetes however, despite being characterized by normal or heightened 
BMD (up to 8% higher than non-diabetic subjects after controlling for confounding 
factors), is also associated with an increase in fracture risk due to inferior bone 
quality196, 197, 199, 208-210.  The impaired bone quality is associated with altered collagen 
crosslinking, build-up of AGEs, and reduced bone turnover211.  Interestingly, the risk of 
fracture in type 2 diabetes appears to have a biphasic distribution, with a reduced 
fracture risk in newly diagnosed diabetics and significantly greater risk with increasing 
duration of the disease212.  
1.3.1 Mechanisms of Skeletal Involvement in Diabetes 
The involvement of the skeleton in diabetes may arise as the combined 
consequence of several mechanisms, including altered regulation of vitamin D, reduced 
calcium absorption in the intestine, and accumulation of AGEs within the bone.  The 
changes in blood chemistry associated with diabetes have also been shown to alter the 
development of marrow MPCs, preventing their proliferation and skewing lineage 
potential in favor of adipogenic development over osteoblastogenesis183, 213, 214.  The 
distinct effects of type 1 and 2 diabetes on bone composition may be explained by a 
disrupted balance between BM-MPC self-renewal and differentiation, with promotion of 
adipogenesis over osteoblastogenesis in type 1 diabetes and at the expense of self-
renewal in type 2 diabetes.  Both diseases result in an altered cellular composition of 
the BM and the microenvironment surrounding VSCs and EPCs, which may mediate 
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EPC dysfunction.  There appear to be several mechanisms underlying the shift in MPC 
developmental potential in diabetes, including hyperinsulinemia, hyperlipidemia, 
hyperglycemia, and the use of certain diabetic medications.  
1.3.1.1 Hyperinsulinemia 
Insulin is responsible for the regulation of a number of different processes in 
adipocytes: the accumulation of triglycerides, increasing glucose transport, enhancing 
the rate of lipogenesis, inhibiting lipolysis, and promoting adipogenic differentiation215.  
In vitro, insulin signalling is requisite to induce adipogenesis in cell culture systems and 
in vivo IR-knockout models are subject to compromised adipogenic differentiation216-220.  
Hyperinsulinemia is often present in the initial stages of type 2 diabetes as pancreatic β-
cell insulin production surges in an attempt to combat increasing peripheral insulin 
resistance221, 222.  Insulin binding activates IR or IGF-1 receptor (IGF1R), which leads to 
the tyrosine phosphorylation of the insulin receptor substrate (IRS) and stimulation of a 
tyrosine signalling pathway involving PI3K and PKB (Figure 1.7)215.  The specific effects 
of insulin on adipocytes occur via two mechanisms.  Firstly, PKB activates mammalian 
target of rapamycin (mTOR), which in turn stimulates sterol regulatory element-binding 
protein 1c (SREBP1c; also known as adipocyte determination and differentiation-
dependent factor 1 or ADD1) to regulate the transcription of adipogenic genes, such as 
fatty acid synthase (FAS) and lipoprotein lipase (LPL)223-226.  PKB also phosphorylates 
forkhead box protein O1 (FOXO1), precluding its entry into the nucleus where it serves 
as a transcriptional repressor of PPARγ227, 228.   
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Figure 1.7.  Hyperinsulinemia promotes adipogenesis in MPCs. 
Binding of insulin to IR or IGF1R stimulates the phosphorylation of IRS, leading to the 
activation of a PI3K/PKB signalling pathway.  This pathway induces the transcription of 
PPARγ and adipocyte-specific genes, such as FAS and LPL. 
[FAS = fatty acid synthase; FOXO1 = forkhead box protein O1; IGF1R = insulin-like 
growth factor-1 receptor; IR = insulin receptor; IRS = insulin receptor substrate; LPL = 
lipoprotein lipase; MPC = mesenchymal progenitor cell; mTOR = mammalian target of 
rapamycin; PI3K = phosphoinositide-3-kinase; PKB = protein kinase B; PPARγ = 
peroxisome proliferator activated receptor γ] 
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Insulin has also been suggested to have anabolic actions on bone229.  
Osteoblasts possess high affinity receptors capable of binding insulin at physiological 
concentrations, and insulin signalling has been shown to be critical for osteogenic 
progenitor cell proliferation, bone mineralization, and bone turnover230-235.  Insulin has 
also been shown to positively influence the survival of osteoblasts in a dose-dependent 
manner236.  As hyperinsulinemia characterizes the early stages of type 2 diabetes, the 
unique effects insulin exerts on osteoblasts may contribute to the increased BMD and 
reduced fracture risk seen in newly-diagnosed diabetic subjects212, 237, 238.  Following β-
cell failure (or in type 1 diabetics), patients devolve into a hypoinsulinemic state, 
preventing the occurrence of these osteo-anabolic effects and potentially contributing to 
the enhanced fracture risk in the type 2 diabetic population with increasing disease 
duration239. 
1.3.1.2 Hyperlipidemia 
 Hyperlipidemia is nearly a universal hallmark of type 2 diabetes and is also a 
frequent comorbidity in type 1 diabetes, particularly when poorly controlled240-242.  
Plasma levels of free fatty acids (FFAs) are elevated in many diabetics and have been 
shown to contribute to the development of insulin resistance and cardiovascular 
disease242-246.  Significant elevations in the relative quantities of di- and tri-unsaturated 
fatty acids relative to saturated fats have also been found in the plasma of non-obese 
diabetic mice247.  PPARγ is capable of serving as a physiological sensor of lipid levels, 
with both mono- and poly-unsaturated fatty acids binding to and activating the 
transcription factor to promote adipogenesis248, 249.  In addition to the effects of fatty 
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acids on undifferentiated cells, treatment of osteoblasts with serum high in fatty acids 
was found to induce their cross-differentiation into adipocytes, as characterized by Oil 
Red O staining and up-regulation of FABP4250.  Diabetes has also been associated with 
increases in the endogenous production of prostaglandins251-253.  Prostaglandins have 
similarly been shown to bind PPARγ to promote adipogenic differentiation, while also 
inhibiting osteoblastogenesis of MPCs254-256. 
1.3.1.3 Hyperglycemia 
1.3.1.3.1 PI3K-PKB Pathway  
 High levels of blood glucose have been demonstrated to increase adipocyte 
formation, lipid accumulation, and the expression of PPARγ in mouse BM-derived 
MSCs257.  It has been suspected that hyperglycemia partially mediates its effects 
through changes to post-receptor insulin signalling, which may be implicated in the 
development of insulin resistance257, 258.  High levels of glucose increases the activity of 
PI3K and the subsequent phosphorylation of PKB, both of which are involved in the 
insulin signalling cascade257, 258.  PKB-facilitated de-repression of the pparγ gene 
though FOXO1 nuclear export leads to the induction of PPARγ and C/EBPα expression, 
along with increased adiposity of the bone marrow257, 259-261. 
1.3.1.3.2 Reactive Oxygen Species 
 As described earlier, diabetes is characterized by overproduction of ROS.  
Excessive movement of electrons through the TCA cycle eventually overwhelms the 
electron transport system and results in the generation of superoxide from molecular 
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oxygen.  Superoxide is then able to inhibit the action of glycolytic enzyme 
glyceraldehyde-3 phosphate (GAPDH), which leads to the stimulation of the AGE 
pathway that has been shown to be increasingly activated in diabetes22, 262, 263.  AGEs 
are proteins or lipids that become glycosylated following exposure to sugars and 
accelerate cellular oxidative damage and have been implicated in both micro- and 
macro-vascular diabetic complications264-267.  Binding of AGEs and their receptors, 
known as RAGE, have been associated with reduced bone formation by osteoblasts 
and diminished matrix mineralization, in addition to impaired osteoblastogenesis268, 269.  
AGE-RAGE interactions have also been identified as promoters of the MPC and 
osteoblast apoptosis, contributing to the depletion of the BM SC niche270, 271.  
Additionally, AGEs in collagen lead to heightened cross-linking and increased stiffness 
of the collagen network, possibly resulting in bone fragility263, 272.  
 Oxidative stress induced by hyperglycemia has also been found to activate the 
PI3K/PKB pathway, which acts to inhibit osteoblastic maturation and stimulate 
adipogenesis273.  Osteoblasts exposed to ROS resultant from high glucose demonstrate 
decreased expression of Runx2 and osteocalcin, with a concomitant increase in the 
abundance of the adipogenesis-related factors PPARγ, adipsin, and aP2273. ROS is 
also able to prevent matrix mineralization and enhance the accumulation of lipid 
droplets in osteoblasts273.  
1.3.1.3.3 Non-Canonical Wnt-PKC Pathway 
While most of the wingless-type MMTV integration site family member (Wnt) 
family of genes are responsible for the negative regulation of adipogenesis, we have 
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shown that Wnt11 may be induced by hyperglycemia to enhance the adipocytic 
differentiation of marrow cells274.  While the mechanism remains to be fully elucidated, 
our current working model is that, through a non-canonical pathway, hyperglycemia 
induces a switch in Wnt11 signalling that differentially activates the various isoforms of 
PKC, specifically inducing the phosphorylation and consequent activation of PKC-γ or -
ε274, 275.  PKC-ε is trans-located from the cytoplasm to the nucleus where it is expressed 
in spatiotemporal symmetry with C/EBPβ, suggesting a potential interaction274, 276.  
Through a currently unknown process likely involving the phosphorylation and 
regulation of key nuclear adipogenic factors, PKC-ε activation results in the acceleration 
of adipocytic differentiation276.  
1.3.1.3.4 Hyperglycemia on Osteoblasts 
 Understanding the effects of excessive glucose on pre-osteoblasts has been 
complicated by the inconsistent definitions of hyperglycemia used by researchers, 
although this also allows for the characterization of a dose-response effect to increasing 
glucose concentrations.  Moderate elevations in glucose level (15 mmol/L) have been 
shown to promote the proliferation and differentiation of pre-osteoblasts via activation of 
the PI3K/PKB signalling pathway, while also significantly reducing calcium uptake and 
deposition277, 278.  As glucose concentration increased to 20-35.5 mM, differentiation of 
pre-osteoblasts and the expression of osteogenic genes progressively decreased278, 279.  
Escalating glucose levels have also been associated with significant increases in ROS, 
as well as apoptosis in mature osteoblasts280.  Hyperglycemia has been shown to down-
regulate pro-osteoblastic genes Runx2, BGLAP, and osteonectin with simultaneous up-
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regulation of adipogenic genes PPARγ, adipsin, and adipocyte protein 2 (aP2), as well 
as lipid accumulation, suggesting the potential for cross-differentiation281, 282.   
Diabetes is characterized by the accelerated formation of AGEs due to the 
greater availability of glucose283.  AGEs are capable of inhibiting the osteoblastic 
differentiation of precursor cell lines via repression of Sp7 independently of 
hyperglycemia284.  Additionally, long-term interactions between AGEs and its receptor, 
RAGE, stimulates the apoptosis of osteoblastic cells both in vitro and in vivo, particularly 
in more mature cell types270.  In addition, the formation of AGEs has been shown to 
increase collagen network stiffness, leading to a reduction in its ductility and contributing 
to the increased susceptibility to fractures in diabetics211, 285.   
1.3.1.4 Effects of Diabetic Medications 
1.3.1.4.1 Thiazolidinediones 
Thiazolidinediones (TZDs or glitazones) are a class of oral anti-diabetic 
medications once commonly prescribed to improve insulin responsiveness that have 
since fallen from favour over concerns regarding their cardiovascular and hepatic 
safety286, 287.  TZDs exert their beneficial effect on insulin resistance through high affinity 
binding to and activation of PPARγ288.  Within adipose deposits, this interaction skews 
the differentiation potential of resident progenitor cells towards the fat cell lineage, 
leading to weight gain289.  In the BM, TZDs skew the development of MPCs by driving 
adipogenesis directly through the induction of PPARγ, while simultaneously suppressing 
osteoblastic development290-293.  Treatment of osteo-adipo precursor cells with TZD 
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results in up-regulation of fat cell-specific factors, such as adipsin and FABP4293.  BM-
MPCs treated with rosiglitazone demonstrate suppression of early markers of 
osteoblastic differentiation, such as Runx2, as well as biochemical indicators of bone 
formation, such as osteocalcin, alkaline phosphatase, and collagen 1293-295.  Others 
have attributed the loss of bone density to TZD-induced apoptosis of osteoblasts and 
mature osteocytes in concomitance with inhibition of bone formation296-298. 
TZDs have been variously reported as having both positive and negative effects 
on the differentiation and function of osteoclasts.  TZDs have been shown to be potent 
inhibitors of osteoclast formation and minimizers of bone resorption299, 300.  Alternatively, 
osteoclast-specific deletion of PPARγ has also been found to result in osteopetrosis and 
increased bone mass, while TZD-mediated stimulation of PPARγ can increase 
osteoclastic differentiation and lead to excessive bone resorption301, 302.  This effect 
appears to be the result of a PPARγ-stimulated increase in the transcription of c-Fos, 
which plays a critical role in the differentiation of osteoclasts301, 303.  Additionally, 
rosiglitazone has been shown to increase the abundance of C-terminal telopeptide in 
some diabetic populations, which serves as a biomarker of osteoclast function, though it 
has also been reported to inhibit osteoclastogenesis and bone resorption295.  
1.3.1.4.2 Insulin Analogues 
As insulin is a well-known inducer of adipogenesis, it is of little surprise that 
starting diabetic patients on exogenous insulin therapy is often associated with a 
significant increase in adiposity.  Type 2 diabetic subjects treated solely with Neutral 
Protamine Hagedorn (NPH) insulin reported an average increase in body weight of 7.5 
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kg over 12 months of therapy304.  This weight gain appears to be a consequence of 
increased lipid accumulation from fully developed fat cells and promotion of the 
adipogenic differentiation of progenitor cells305.  Interestingly, not all insulin analogues 
have an identical effect on progenitor cells, with lower mRNA expression of adipogenic 
markers PPARγ and leptin among preadipocytes treated with insulin detemir305-307.  
Insulin detemir has been shown to have a minimal effect on MPC differentiation or 
weight gain relative to other insulin formulations305, 308-310.  This may be a function of the 
medication’s reduced affinity for the insulin receptor, though treatment of preadipocytes 
with both equimolar and equipotent concentrations of insulin detemir resulted in 
significantly less differentiation than did treatment with human insulin305, 306, 311.  
Specifically in regards to bone, treatment of type 2 diabetics with insulin therapy has 
been associated with an increased risk of fractures312, 313.  
1.3.1.4.3 Metformin 
 Metformin is the often the first-line pharmacological therapy of choice in the 
management of type 2 diabetes314.  Metformin is an orally administered biguanide that 
moderates plasma glucose levels by suppressing excessive hepatic 
gluconeogenesis315.  Unlike many other anti-diabetic medications, metformin is not 
associated with increased enhanced adipogenesis or weight gain, and in many cases, 
actually leads to a reduction in weight316, 317.  A retrospective chart review of type 2 
diabetics treated with metformin alone identified a significant increase in BMD, while 
joint therapy with metformin and insulin failed to produce this increase318.  Other studies 
have similarly confirmed a decrease in the risk of fractures among diabetics treated with 
  
37 
metformin319, 320.  In vivo animal models have shown increased BMD and bone 
formation when treated with metformin, while the administration of metformin to in vitro 
culture systems appears to promote osteoblastic differentiation of MPCs and inhibit 
adipogenesis321-326.  Metformin increases the expression of several biochemical 
markers of bone formation among osteoblasts, such as alkaline phosphatase, collagen 
1, and BGLAP323.  Metformin also enhances the production of osteoprotegerin, an 
osteoclast-inhibitory factor, and decreases the expression of the osteoclast-stimulating 
factor RANKL by osteoblastic cells to reduce bone turnover321. 
Metformin has been shown to increase bone density by promoting the osteogenic 
differentiation of MPCs both in vitro and in vivo, with up-regulation of osteoblastic 
transcription factor Runx2 and no discernable effect on PPARγ, potentially leading to a 
slight reduction in fracture risk319, 322-324.  This enhanced osteogenesis appears to be the 
result of increased activation of AMP-activated protein kinase (AMPK) leading to up-
regulation of eNOS and BMP2324, 327, 328.  Metformin may also reduce levels of 
sclerostin, an osteocyte-produced glycoprotein with anti-anabolic effects on bone 
through Wnt and β-catenin signalling to enhance bone density318.  
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1.4 Rationale 
 Previously, the primary role of adipocytes was believed to be energy storage, 
though as of late, an important regulatory function for adipocytes has been realized.  
Adipocytes are now recognized as acting systemically through the production of 
hormones such as adiponectin, resistin, and leptin, as well as acting locally via the 
actions of an assortment of cytokines.  We believe that diabetes-induced shift in the 
developmental potential of BM-MPCs leads to the formation of a unique cellular 
composition within the BM, skewed in favor of adipocytes.  Studies of numerous other 
SC types have established the importance of the extracellular environment surrounding 
SCs in guiding cellular differentiation.  Many studies have investigated the role of the 
BM hematopoietic SC niche on HSC development, including variations of the niche 
within the context of disease states such as diabetes193, 329-331.  Interestingly, relatively 
little has been written about the interactions between the BM microenvironment and 
resident VSCs and EPCs, even though the cell types are significant contributors to 
vascular health.  The interactions between VSCs/EPCs, BM stromal cells, and other BM 
components that govern the differentiation and release of EPCs into circulation are 
poorly understood46.  Elucidating the mechanism by which diabetes leads to 
impairments in EPC survival, migration, and proliferation may provide a novel 
therapeutic approach for the prevention and management of diabetic complications. 
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1.5 Hypothesis 
 I hypothesize that the diabetes-induced changes in the differentiation potential of 
BM-MPCs alters the composition of the BM SC niche in a way which significantly 
impairs resident VSC survival.  
1.6 Specific Aims 
In order to test out hypothesis, I established three primary objectives: 
1. To construct an in vitro niche modelling system to assess the impact that co-
culture with MPCs, adipocytes, and osteoblasts have on the survival and 
adherence of CD133-expressing VSCs 
2. To identify genes that are differentially regulated by adipocytes and osteoblasts 
relative to MPCs that may affect the properties of VSCs 
3. To utilize a rat model of diabetes to correlate our in vitro gene expression data to 
an in vivo model of diabetes 
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Chapter 2 : Materials and Methods 
2 Materials and Methods 
2.1 In Vitro Studies 
I derived BM-MPCs from cultures of BM mononuclear cells (MNCs; Lonza Inc., 
Walkersville, MD) on plastic tissue culture dishes coated with 1 μg/cm2 fibronectin (FN) 
(Millipore, Temecula, CA) in complete Endothelial Basal Media-2 (EBM-2; Lonza Inc.) 
supplemented with 20% fetal bovine serum (FBS; Life Technologies, Burlington, ON), 
1% antibiotic-antimycotic solution of penicillin, streptomycin, and fungizone 
(amphotericin) (PSF; Mediatech Inc., Manassas, VA), and SingleQuots (Lonza Inc.) 
containing VEGF, IGF-1, human epidermal growth factor, human basic fibroblast growth 
factor, ascorbic acid, heparin, hydrocortisone, and gentamicin/amphotericin B.  The 
media was changed three times per week.  Cultures were maintained in an incubator 
with 5% CO2 at 37
oC.  In order to generate human adipocytes and osteoblasts, I 
prepared BM-MPCs as described above, with the exception of FN coating of culture 
dishes.  I then induced differentiation by exposing cells seeded at a density of 50,000 
cells/cm2 to specific differentiation media.  Differentiation into adipocytes was induced 
through a seven-day culture of BM-MPCs in StemPro Adipogenesis Differentiation 
Media (Life Technologies), supplemented with 1% PSF.  BM-MPC differentiation into 
osteoblasts was induced through a 14-day culture of confluent BM-MPCs in StemPro 
Osteogenesis Differentiation Media (Life Technologies) with 1% PSF.  Differentiation 
media were changed three times per week.  
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 I utilized PoieticsTM human umbilical cord blood CD133+ cells (Lonza Inc.) to 
serve as VSCs, as CD133 is, at present, the single best marker of precursor cells with 
endothelial potential145, 147.  Our laboratory and others have previously shown derivation 
of outgrowth EPCs from CD133+ umbilical cord and bone marrow cells143, 332, 333.  As 
the expression of CD133 tends to be lost very rapidly in these cells upon culture, I 
utilized the cells without prior culture in all experiments in order to minimize variability146.  
For some experiments, I maintained CD133+ cells in short-term culture in complete 
EBM-2, with 20% FBS, 1% PSF, and SingleQuots.  For co-culture experiments, 10,000 
CD133+ cells/cm2 were seeded onto confluent cultures of BM-MPCs, or MPC-derived 
adipocytes or osteoblasts and maintained for one to 21 days.  Twenty-one days was 
selected as a suitable endpoint in order to allow for the potential differentiation of 
CD133+ cells into ECs, which occurs after approximately three weeks of culture143, 334. 
2.2 In Vivo Model 
 All experiments were conducted in accordance with Western University and 
Animal Care and Veterinary Services Guidelines. Six-week old male Sprague-Dawley 
rats (175 g) were obtained from Charles River (Wilmington, MA).  A single 
intraperitoneal injection of 65 mg/kg streptozotocin (STZ) in a pH 5.6 citrate buffer was 
administered.  Control animals were subjected to an intraperitoneal injection of an 
equivalent volume of citrate buffer alone.  Changes in body weight and blood glucose in 
rats were monitored for four weeks following STZ injections and confirmation of 
hyperglycemia.  After four weeks, the rats were then euthanized and their femurs were 
extracted.  Four weeks has previously been shown to be a sufficient length of time to 
  
42 
elicit significant changes in skeletal composition and bone deposition in models of STZ-
induced diabetes in both mice and rats335-338. 
2.2.1 RNA Isolation from Marrow Samples for qPCR 
 The BM of the medullary cavity of femurs of each rat was then extracted in order 
to conduct gene expression analyses.  To remove the BM, the epiphyses of the bones 
were removed, followed by centrifugation of the diaphyses at 200 xg for 12 minutes.  
The resulting fluid was then suspended in RLT lysis buffer (from RNeasy Mini Plus kit; 
Qiagen, Mississauga, ON) before being passed through an 18-gauge syringe. 
2.3 Measurement & Assessment 
2.3.1 RNA Isolation and qRT-PCR 
 Total RNA was extracted from cells and isolated rat marrow using RNeasy Mini 
Plus kits and according to established protocol339.  cDNA was synthesized using iScript 
Reverse Transcription Supermix (Bio-Rad Laboratories, Inc., Mississauga, ON) and the 
PTC-100 Thermal Cycler (MJ Research, St. Bruno, QC).  Quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) was conducted using custom 
PrimePCR arrays (Bio-Rad Laboratories, Inc.) (Tables 2.1 and 2.2) or individual primers 
as listed in Tables 2.3 and 2.4 (Qiagen).  PCR reactions for in vitro experiments 
consisted of 10 µL of SsoFast Evagreen Supermix (Bio-Rad Laboratories, Inc.), 1 µL of 
cDNA, 1 µL of forward and reverse primers at 10 µM (except when using PrimePCR 
arrays), and 8-9 µL nuclease-free H2O (total reaction volume of 20 µL).  PCR reactions 
for in vivo experiments utilized 10 µL of RT2 SYBR Green Mastermix (Qiagen), 2 µL of  
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Table 2.1.  Primer sequence information for niche gene qRT-PCR custom plate 
array. 
Gene Species Length (bp) Source (Catalogue 
Number/Assay ID) 
SC Markers 
CD90 Human 120 bp Bio-Rad (qHsaCED0036661) 
CD133 Human 146 bp Bio-Rad (qHsaCID0017657) 
cKit Human 63 bp Bio-Rad (qHsaCID0008692) 
Nanog Human 116 bp Bio-Rad (qHsaCED0023824) 
Octamer-binding 
transcription factor 4 
(Oct4) 
Human 100 bp Bio-Rad (qHsaCED0038334) 
SCF Human 63 bp Bio-Rad (qHsaCID0008692) 
Human 115 bp Bio-Rad (qHsaCID0008103) 
Sox2 Human 98 bp Bio-Rad (qHsaCED0036871) 
Endothelial Markers 
VE-cadherin Human 112 bp Bio-Rad (qHsaCID0016288) 
vWF Human 113 bp Bio-Rad (qHsaCED0033955) 
Hematopoietic Markers & Signalling 
CD34 Human 99 bp Bio-Rad (qHsaCID0007456) 
CD45 Human 69 bp Bio-Rad (qHsaCED0038908) 
Hemoglobin-α1 
(HBA1) 
Human 90 bp Bio-Rad (qHsaCED0020775) 
Myeloproliferative 
leukemia protein 
(MPL) 
Human 119 bp Bio-Rad (qHsaCID0015934) 
Thrombopoietin 
(THPO) 
Human 92 bp Bio-Rad (qHsaCED0002654) 
  
44 
 
Adipogenic Markers 
C/EBP-α Human 69 bp Bio-Rad (qHsaCED0019045) 
C/EBP-β Human 117 bp Bio-Rad (qHsaCED0019041) 
PPARγ Human 117 bp Bio-Rad (qHsaCID0011718) 
Osteogenic Markers 
BGLAP Human 69 bp Bio-Rad (qHsaCED0038437) 
Runx2 Human 80 bp Bio-Rad (qHsaCID0006726) 
Sp7 Human 139 bp Bio-Rad (qHsaCED0003759) 
BMP Signalling 
BMP4 Human 127 bp Bio-Rad (qHsaCED0003208) 
BMP4R1A Human 164 bp Bio-Rad (qHsaCED0003308) 
BMP4R1B Human 120 bp Bio-Rad (qHsaCID0021330) 
BMP4R2 Human 119 bp Bio-Rad (qHsaCID0008240) 
Notch Receptors    
NOTCH1 Human 141 bp Bio-Rad (qHsaCID0011825) 
NOTCH2 Human 72 bp Bio-Rad (qHsaCED0005739) 
NOTCH3 Human 115 bp Bio-Rad (qHsaCID0006529) 
NOTCH4 Human  163 bp Bio-Rad (qHsaCID0037298) 
Notch Ligands    
Delta-like ligand 1 
(DLL1) 
Human 100 bp Bio-Rad (qHsaCID0011257) 
Human 110 bp Bio-Rad (qHsaCED0048350) 
DLL3 Human 100 bp Bio-Rad (qHsaCED0003364) 
DLL4 Human 84 bp Bio-Rad (qHsaCID0008450) 
Jagged-1 (JAG1) Human 99 bp Bio-Rad (qHsaCID0006831) 
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Human 96 bp Bio-Rad (qHsaCED0042862) 
JAG2 Human 127 bp Bio-Rad (qHsaCED0003193) 
Human 72 bp Bio-Rad (qHsaCED0047702) 
Angiopoietin (Ang) Signalling 
Ang1 Human 140 bp Bio-Rad (qHsaCID0008671) 
Ang2 Human 148 bp Bio-Rad (qHsaCID0017615) 
Tie-1 Human 75 bp Bio-Rad (qHsaCID0006540) 
Human 115 bp Bio-Rad (qHsaCED0042231) 
Tie-2 Human 101 bp Bio-Rad (qHsaCID0015119) 
Cell Adhesion Molecules 
CD38 Human 110 bp Bio-Rad (qHsaCID0006586) 
Integrin-α4 Human 73 bp Bio-Rad (qHsaCID0007441) 
Integrin-β1 Human 104 bp Bio-Rad (qHsaCED0005248) 
Neuronal cadherin 
(N-cadherin) 
Human 151 bp Bio-Rad (qHsaCID0015189) 
Vascular cell 
adhesion molecule 
(VCAM) 
Human 137 bp Bio-Rad (qHsaCID0016779) 
SDF-1 Signalling 
SDF-1 Human 94 bp Bio-Rad (qHsaCID0012398) 
C-X-C chemokine 
receptor 4 (CXCR4) 
Human 142 bp Bio-Rad (qHsaCED0002020) 
Immunoglobulin Superfamily Genes 
CD33 Human 148 bp Bio-Rad (qHsaCID0006439) 
Telomerase 
Telomerase reverse 
transcriptase (TERT) 
Human 150 bp Bio-Rad (qHsaCID0009247) 
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Housekeeping Genes 
β-actin Human 62 bp Bio-Rad (qHsaCED0036269) 
β2-microglobulin Human 123 bp Bio-Rad (qHsaCID0015347) 
Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH) 
Human 117 bp Bio-Rad (qHsaCED0038674) 
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Table 2.2.  Primer sequence information for ECM gene qRT-PCR custom plate 
array. 
Gene Species Length (bp) Source (Catalogue 
Number/Assay ID) 
A Distintegrin and Metalloproteinase (ADAM) Peptidases 
ADAM 9 Human 144 bp  Bio-Rad (qHsaCID0018553) 
ADAM 10 Human 95 bp Bio-Rad (qHsaCED0001377) 
ADAM 12 Human 99 bp Bio-Rad (qHsaCID0011870) 
ADAM 17 Human 103 bp  Bio-Rad (qHsaCID0016420) 
ADAM 19 Human 67 bp Bio-Rad (qHsaCID0008717) 
ADAM 20 Human 98 bp Bio-Rad (qHsaCED0003133) 
ADAM 21 Human 148 bp  Bio-Rad (qHsaCED0019636) 
ADAM 28 Human 112 bp  Bio-Rad (qHsaCED0004497) 
ADAM 30 Human 114 bp Bio-Rad (qHsaCED0006925) 
ADAM 33 Human 113 bp Bio-Rad (qHsaCED0001073) 
MMPs 
MMP 1 Human 69 bp Bio-Rad (qHsaCID0017039) 
MMP 2 Human 144 bp Bio-Rad (qHsaCID0015623) 
MMP 3 Human 148 bp  Bio-Rad (qHsaCID0006170) 
MMP 7 Human 138 bp Bio-Rad (qHsaCID0011537) 
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MMP 8 Human 135 bp Bio-Rad (qHsaCID0023232) 
MMP 9 Human 82 bp Bio-Rad (qHsaCID0011597) 
MMP 10 Human 69 bp Bio-Rad (qHsaCID0008481) 
MMP 11 Human 139 bp Bio-Rad (qHsaCID0022136) 
MMP 13 Human 138 bp Bio-Rad (qHsaCID0008487) 
MMP 14 Human 60 bp Bio-Rad (qHsaCED0001628) 
MMP 15 Human 84 bp Bio-Rad (qHsaCED0002668) 
MMP 16 Human 66 bp Bio-Rad (qHsaCID0016162) 
MMP 17 Human 164 bp  Bio-Rad (qHsaCED0005565) 
MMP 19 Human 93 bp Bio-Rad (qHsaCID0010428) 
MMP 24 Human 118 bp Bio-Rad (qHsaCID0017196) 
MMP 25 Human 91 bp Bio-Rad (qHsaCED0004540) 
Tissue Inhibitors of Metalloproteinases (TIMPs) 
TIMP 1 Human 82 bp Bio-Rad (qHsaCID0007434) 
TIMP 2 Human 145 bp Bio-Rad (qHsaCID0022953) 
TIMP 3 Human 119 bp Bio-Rad (qHsaCID0015238) 
TIMP 4 Human 77 bp Bio-Rad (qHsaCID0016129) 
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Aminopeptidases 
Glutamyl 
Aminopeptidase 
(Aminopeptidase 
A) 
Human 79 bp Bio-Rad (qHsaCID0014953) 
Fibronectin & Inhibitors 
Fibronectin Human 138 bp Bio-Rad (qHsaCID0012349) 
Tenascin C Human 125 bp Bio-Rad (qHsaCID0020888) 
Collagens 
Collagen 1A1 Human 114 bp Bio-Rad (qHsaCED0002181) 
Collagen 2A1 Human 102 bp Bio-Rad (qHsaCED0001057) 
Collagen 3A1 Human 90 bp Bio-Rad (qHsaCID0014986) 
Collagen 4A4 Human 114 bp Bio-Rad (qHsaCID0016411) 
Collagen 5A1 Human 193 bp Bio-Rad (qHsaCID0014514) 
Collagen 6A1 Human 90 bp Bio-Rad (qHsaCID0007091) 
Basement Membrane Component Proteins 
Laminin C1 Human 104 bp Bio-Rad (qHsaCID0006254) 
Laminin C2 Human 150 bp Bio-Rad (qHsaCID0021924) 
Laminin C3 Human 119 bp Bio-Rad (qHsaCID0018418) 
Nidogen 1 Human 106 bp Bio-Rad (qHsaCED0036445) 
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Nidogen 2 Human 127 bp Bio-Rad (qHsaCID0009675) 
Heparan Sulfate 
Heparan sulfate 
proteoglycan 2 
(HSPG2) 
Human 69 bp Bio-Rad (qHsaCED0036599) 
Housekeeping Genes 
β-actin Human 62 bp Bio-Rad (qHsaCED0036269) 
β2-microglobulin Human 123 bp Bio-Rad (qHsaCID0015347) 
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Table 2.3.  Primer sequence information for qRT-PCR individual primers used for 
in vitro experimental analyses. 
Gene Species Length (bp) Source (Catalogue 
Numbers/Assay ID) 
SC Markers 
CD133 Human 105 bp Qiagen (QT00075586) 
Nanog Human 90 bp Qiagen (QT01025850) 
Oct4 Human 77 bp Qiagen (QT00210840) 
Sox2 Human 64 bp Qiagen (QT00237601) 
Endothelial Markers 
CD31 Human 144 bp Qiagen (QT00081172) 
Adipogenic Markers 
C/EBP-α Human 88 bp Qiagen (QT00203357) 
C/EBP-β Human 121 bp Qiagen (QT00237580) 
C/EBP-δ Human 90 bp Qiagen (QT00219373) 
PPARγ Human 113 bp Qiagen (QT00029841) 
FABP4 Human 100 bp Qiagen (QT01667694) 
Angiopoietin Signalling 
Ang1 Human 111 bp Qiagen (QT00046865) 
Ang2 Human 79 bp Qiagen (QT00100947) 
Tie-1 Human 63 bp Qiagen (QT00013797) 
Tie-2 Human 134 bp Qiagen (QT01666322) 
Cell Cycling Molecules 
Cyclin D1 Human 96 bp Qiagen (QT00495285) 
Housekeeping Genes 
β-actin Human 104 bp Qiagen (QT01680476) 
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Table 2.4.  Primer sequence information for qRT-PCR primers used for in vivo 
experiment analyses. 
Gene Species Length (bp) Source (Catalogue 
Numbers/Assay ID) 
SC Markers 
Nanog Rat 112 bp Qiagen (QT01300579) 
Oct4 Rat 134 bp Qiagen (QT00455028) 
Sox2 Rat 128 bp Qiagen (QT00544649) 
Endothelial Markers 
CD31 Rat 96 bp Qiagen (QT01289939) 
VEGFR2 Rat 118 bp Qiagen (QT00408352) 
vWF Rat 107 bp Qiagen (QT01588713) 
MPC Markers 
CD73 Rat 93 bp Qiagen (QT00190876) 
CD90 Rat 82 bp Qiagen (QT00195825) 
CD105 Rat 65 bp Qiagen (QT00492870) 
Adipogenic Markers 
C/EBP-α Rat 63 bp Qiagen (QT00395010) 
C/EBP-β Rat 113 bp Qiagen (QT00366478) 
C/EBP-δ Rat 94 bp Qiagen (QT00368599) 
PPARγ Rat 146 bp Qiagen (QT00186172) 
FABP4 Rat 127 bp Qiagen (QT01290072) 
Osteogenic Markers 
BGLAP Rat 92 bp Qiagen (QT00371231) 
Runx2 Rat 172 bp Qiagen (QT01300208) 
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Sp7 Rat 111 bp Qiagen (QT00423206) 
Angiopoietin Signalling 
Ang1 Rat 92 bp Qiagen (QT00199346) 
Ang2 Rat 89 bp Qiagen (QT01592045) 
Tie-1 Rat 106 bp Qiagen (QT01592031) 
Tie-2 Rat 133 bp Qiagen (QT01592038) 
ECM Genes 
Collagen 1A1 Rat 92 bp Qiagen (QT00370622) 
Collagen 4A4 Rat 108 bp Qiagen (QT02346085) 
Collagen 6A1 Rat 73 bp Qiagen (QT00440839) 
Fibronectin Rat 92 bp Qiagen (QT00179333) 
Chemokines 
SDF-1 Rat 120 bp Qiagen (QT00194152) 
Housekeeping Genes 
β-actin Rat 145 bp Qiagen (QT00193473) 
  
54 
cDNA, and 8 µL of nuclease-free H2O, for a total reaction volume of 20 µL.  PCR 
reactions were performed at the temperature profiles outlined in Table 2.5 and Table 2.6 
for SsoFast EvaGreen Supermix and qBiomarker SYBR Green Fluor Mastermix, 
respectively, using the CFX Connect Real Time PCR Detection System (Bio-Rad 
Laboratories, Inc.).  Data were analyzed according to the ΔΔCT method using CFX 
Manager Software (Bio-Rad Laboratories, Inc.) and normalized to β-actin expression. 
2.3.2 Immunofluorescence Cell Staining 
 BM-MPCs were cultured and induced to differentiate as described above on 
collagen 1-coated 4- or 8-chambered slides.  CD133+ cells were overlaid for 48 hours 
and culture slides were then stained for SC markers through one hour incubations of 
cells at room temperature using primary antibodies (Table 2.7).  Subsequent to the 
primary antibody incubation, cells were incubated with the appropriate Alexa488-
conjugated secondary antibody (Life Technologies) for one hour at room temperature.  
Slides were then counterstained using ProLong® Diamond Antifade Mountant with 
DAPI (Life Technologies).  Imaging was performed using the Olympus BX-51 
fluorescent microscope (Olympus Canada Inc., Richmond Hill, ON) and SPOT Basic 
Image Capture & SPOT Advanced Microscope Imaging Software (SPOT Imaging 
Solutions, Sterling Heights, MA). 
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Table 2.5.  Temperature profiles for qRT-PCR with SsoFast EvaGreen Supermix. 
Cycling Step Temperature Time (min:sec) No. of Cycles 
Enzyme Activation 95oC 2:00 1 
Denaturation 95oC 0:02 
45 
Annealing/Extension 55oC 0:12 
 
Melt Curve 
 
65oC 
+ 0.2oC to 95oC 
0:10 / step 1 
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Table 2.6.  Temperature profiles for qRT-PCR with qBiomarker SYBR Green Fluor 
Mastermix. 
Cycling Step Temperature Time (min:sec) No. of Cycles 
Enzyme Activation 95oC 10:00 1 
Denaturation 95oC 0:15 
40 
Annealing/Extension 60oC 1:00 
 
Melt Curve 
 
65oC 
+ 0.5oC to 95oC 
0:10 / step 1 
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Table 2.7.  Primary antibodies used for immunofluorescence staining. 
Antigen Host Source (Catalogue 
Number) 
Dilution 
CD133 Rabbit polyclonal Abcam (ab19898) 1:200 
Sox2 Goat polyclonal R&D Systems (AF2018) 1:200 
Nanog Rabbit polyclonal Abcam (ab21624) 1:200 
Oct4 Rabbit polyclonal Abcam (ab19857) 1:200 
Ki67 Rabbit monoclonal Abcam (ab16667) 1:200 
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2.3.3 Statistical Analyses 
 Data are expressed as mean expression ± standard error of the mean (SEM).  
Significance was determined using two-tailed student’s unpaired t-tests.  P-values < 
0.10 were considered to be statistically significant. 
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Chapter 3 : Results 
3 Results 
3.1 Effect of ECM Substrates on Adipogenesis 
 My first objective was to establish adipogenic differentiation of BM-MPCs to be 
used in creating an in vitro SC niche.  In order to enhance MPC adhesion to glass 
chamber plates, surfaces are typically coated in a FN substrate to improve cell 
adherence.  It has previously been demonstrated that FN may significantly alter MPC 
differentiation, including inhibition of adipogenesis340-344.  To evaluate the impact FN has 
on adipogenesis and to identify a novel coating substrate that does not interfere with 
adipogenic differentiation, BM-MPCs were cultured on uncoated plastic culture dishes, 
or plastic dishes coated with 1 μg/cm2 FN or 10 μg/cm2 type 1 collagen.  MPCs were 
induced to develop into adipocytes through culture in the appropriate differentiation 
medium for seven days.  I observed a delay in adipogenic differentiation on FN-coated 
plates, with increased expression of early differentiation factor C/EBP-β and repression 
of late adipogenic marker PPARγ (Figure 3.1).  Collagen 1-coated plates appeared to 
have no significant effect on adipogenesis, identifying it as a suitable substrate for 
cultures involving MPC differentiation. 
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Figure 3.1.  Effect of ECM substrates on adipogenesis. 
BM-MPCs were induced to differentiate into adipocytes over seven days on uncoated 
plastic culture dishes, or plates coated with 10 μg/cm2 collagen 1 or 1 μg/cm2 FN.  FN 
appeared to delay adipogenesis, with up-regulation of early adipogenic marker C/EBP-β 
and repression of late marker PPARγ.  Collagen 1 coating did not have any significant 
effects on the expression of markers of adipogenic differentiation. 
[C/EBP = CCAAT-enhancer-binding protein; ECM = extracellular matrix; FABP4 = fatty 
acid binding protein 4; PPARγ = peroxisome proliferator-activated receptor gamma] 
[* p < 0.05 compared to uncoated plate control; data expressed as mean ± SEM, 
normalized to β-actin expression and expressed as fold difference of uncoated plate 
control] 
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3.2 Establishing Co-culture of CD133-Positive Cells with 
Adipocytes and Osteoblasts 
 Based on the results garnered from the previous experiment, collagen 1 was 
selected as an ECM substrate for coating of glass chamber slides with minimal 
interference on differentiation.  Chamber slides were incubated for 3 hours with 10 
μg/cm2 collagen 1 in acetic acid collagen coating buffer.  BM-MPCs were seeded at a 
high density and induced to differentiate into adipocytes or osteoblasts.  CD133+ cells 
were then added to each chamber slide system at a cell density of 10,000 cells/cm2.  
After 48 hours of co-culture, slides were subjected to immunofluorescence microscopy 
for CD133, Nanog, and Oct4.  Figures 3.2-3.4 serve as representative images 
demonstrating CD133+ cells in co-culture with MPCs, adipocytes, and osteoblasts after 
48 hours of culture.  Although I detected CD133+ cells in these cultures, the numbers 
were too low for proper quantification (Figures 3.2-3.4).  Therefore, I explored the 
possibility of using qPCR to quantify CD133 and other SC markers as a measure of the 
quantity of SCs in each culture.  qRT-PCR was performed on CD133+ cells, MPCs, 
adipocytes, and osteoblasts in order to determine the expression of SC markers CD133, 
Nanog, and Oct4.  CD133+ cells were positive for the expression of CD133, with no 
detection of CD133 mRNA in MPCs, adipocytes, or osteoblasts (Figure 3.5).  Further, 
CD133+ cells were also positive for Oct4 and Nanog mRNA.  The undetectable level of 
CD133, Nanog, and Oct4 in MPCs, adipocytes, and osteoblasts supported the use of 
these three factors as identifiers of the SC phenotype within this co-culture system. 
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Figure 3.2.  Immunofluorescence staining of CD133+ cells in BM-MPC co-culture. 
CD133-positive SCs were cultured for 48 hours in co-culture with BM-MPCs before 
being stained for the expression of SC markers, CD133, Nanog, and Oct4.   
[20x magnification] 
[Oct4 = octamer-binding transcription factor 4]  
DAPI Merged CD133 
Nanog 
Oct4 
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Figure 3.3.  Immunofluorescence staining of CD133+ cells in adipocytic co-
culture. 
CD133-positive SCs were cultured for 48 hours in co-culture with adipocytes before 
being stained for the expression of SC markers, CD133, Nanog, and Oct4.   
[Taken at 20x magnification] 
[Oct4 = octamer-binding transcription factor 4] 
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Figure 3.4.  Immunofluorescence staining of CD133+ cells in osteoblastic co-
culture. 
CD133-positive SCs were cultured for 48 hours in co-culture with osteoblasts before 
being stained for the expression of SC markers, CD133, Nanog, and Oct4.   
[Taken at 20x magnification] 
[Oct4 = octamer-binding transcription factor 4] 
DAPI Merged CD133 
Nanog 
Oct4 
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Figure 3.5.  SC gene expression in CD133+ cells, MPCs, adipocytes, and 
osteoblasts. 
There was no detectable expression of CD133, Oct4, or Nanog in MPCs or MPC-
derived adipocytes and osteoblasts. 
[* p < 0.05, ** p < 0.01, *** p < 0.001 compared to CD133-positive SC controls; data 
expressed as mean ± SEM, normalized to β-actin and expressed as fold difference of 
CD133+ cells] 
[MPCs = mesenchymal progenitor cells; Oct4 = octamer-binding transcription factor 4] 
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3.3 Effect of Co-culturing CD133-Positive Cells with BM-MPCs, 
Adipocytes, or Osteoblasts 
 BM-MPCs and BM-MPC-derived adipocytes and osteoblasts were cultured with 
CD133-positive SCs for one or 21 days with regular media changes three times per 
week, aspirating existing media containing any non-adherent cells.  After 21 days of co-
culture, qRT-PCR was performed to quantify the expression of three SC markers, 
CD133, Nanog, and Oct4, to serve as proxies for “stemness” of the cells remaining in 
culture.  There was a significant reduction in the mRNA levels of CD133 in co-culture 
with MPCs after 21 days, with non-significant decreases in the mRNA abundance of the 
two other stem cell markers Nanog and Oct4 (Figure 3.6).  A similar pattern occurred 
following co-culture with adipocytes (Figure 3.7).  In osteoblasts however, relatively 
greater expression of CD133, Nanog, and Oct4 were noted after 21 days as compared 
to day 1 (Figure 3.8).  These results may indicate an increased number of SCs in 
osteoblast co-culture or induction of SC genes.  
 I next set out to analyze the effect BM-MPCs, BM-MPC-derived adipocytes, and 
BM-MPC-derived osteoblasts have on CD133-positive SCs in a modified survival assay.  
CD133+ cells were again co-cultured with MPCs, adipocytes, and osteoblasts for one or 
21 days.  Media changes were conducted three times per week, in which existing media 
was aspirated and any non-adherent cells were centrifuged and seeded back with fresh 
media.  qRT-PCR was performed after one and 21 days in order to evaluate the 
expression of SC markers CD133, Nanog, and Oct4.   
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Figure 3.6.  SC gene expression in adherence co-culture of CD133+ cells with 
MPCs. 
After one and 21 days of co-culture of CD133+ cells with BM-MPCs, the expression 
levels of three SC markers (CD133, Nanog, and Oct4) were quantified as a measure of 
the stemness of cells remaining in culture.  Relative to one day of co-culture, there was 
a significant reduction in the mRNA abundance of CD133, with non-significant 
reductions in Nanog and Oct4.   
[*** p < 0.001 compared to one-day MPC co-culture controls; data expressed as mean ± 
SEM, normalized to β-actin and expressed as fold change of one-day MPC co-culture 
controls] 
[Oct4 = octamer-binding transcription factor 4] 
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Figure 3.7.  SC gene expression in adherence co-culture of CD133+ cells with 
adipocytes.   
After one and 21 days of co-culture of CD133+ cells with BM-MPC-derived adipocytes, 
the expression levels of three SC markers (CD133, Nanog, and Oct4) were quantified 
as a measure of the stemness of cells remaining in culture.  Relative to one day of co-
culture with adipocytes, there was a significant reduction in the mRNA abundance of 
CD133, with non-significant reductions in Nanog and Oct4.  
[*** p < 0.001 compared to one-day adipocyte co-culture controls; data expressed as 
mean ± SEM, normalized to β-actin and expressed as fold change of one-day adipocyte 
co-culture controls] 
[Oct4 = octamer-binding transcription factor 4] 
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Figure 3.8.  SC gene expression in adherence co-culture of CD133+ cells with 
osteoblast co-culture. 
After one and 21 days of co-culture of CD133+ cells with BM-MPC-derived osteoblasts, 
the expression levels of three SC markers (CD133, Nanog, and Oct4) were quantified 
as a measure of the stemness of cells remaining in culture.  Relative to one day of co-
culture with osteoblasts, there were substantial increases in the mRNA abundance of 
Nanog and Oct4.   
[* p < 0.001 compared to one-day osteoblast co-culture controls; data expressed as 
mean ± SEM, normalized to β-actin and expressed as fold change of one-day 
osteoblast co-culture controls] 
[Oct4 = octamer-binding transcription factor 4] 
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After one day of co-culture (Figure 3.9), there were only minor, non-significant 
differences in the mRNA levels of the three SC markers investigated.  However after 21 
days (Figure 3.10), there was a significant reduction in the mRNA levels of each of the 
SC markers in co-culture with adipocytes, suggesting that adipocytes may impair the 
survival of CD133-positive SCs, either by reducing cell numbers or down-regulation of 
SC genes. 
 One potential explanation for the differences observed in my model systems may 
be differential rates of proliferation of the background cell populations, modifying the 
mRNA abundance of the chosen housekeeping gene, β-actin, to dilute the expression of 
our genes of interest.  To eliminate this as a possibility, BM-MPCs were induced to 
differentiate into adipocytes and osteoblasts on chamber slides before being stained 
with the Ki67 to identify proliferating cells.  Under these experimental settings, Ki67-
positive MPCs, adipocytes, or osteoblasts were rarely found (Figure 3.11 A, C, & E).  
Few dividing cells may be seen in culture with each of the three cell types under high 
magnificantion (Figure 3.11 B, D, & F). 
3.4 BM-MPC, Adipocyte, and Osteoblast Contribution to SC 
Niche 
 After establishing alterations in CD133+ cell phenotype (due to either survival, 
adherence, or gene expression changes), I wanted to investigate the potential 
mechanisms underlying these changes.  Therefore, I utilized qRT-PCR to quantify 
differences in the gene expression of various genes involved in ECM composition and   
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Figure 3.9.  SC gene expression in CD133+ cell co-cultures for survival after one 
day. 
CD133+ cells were cultured in co-culture systems with BM-MPCs or MPC-derived 
adipocytes or osteoblasts with modified media changes to assess SC survival.  After 
one day of co-culture, SC markers CD133, Nanog, and Oct4 were quantified.  The 
expression levels of each of the three SC markers were consistent across culture with 
each of the cell types.   
[† p < 0.1 compared to one-day BM-MPC co-culture controls; data expressed as mean 
± SEM, normalized to β-actin and expressed as fold change of one-day BM-MPC co-
culture controls] 
[MPCs = mesenchymal progenitor cells; Oct4 = octamer-binding transcription factor 4] 
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Figure 3.10.  SC gene expression in CD133+ cell co-culture for survival after 21 
days. 
CD133+ cells were cultured in co-culture systems with BM-MPCs or MPC-derived 
adipocytes or osteoblasts with modified media changes to assess SC survival.  After 21 
days of co-culture, SC markers CD133, Nanog, and Oct4 were quantified.  While BM-
MPCs and osteoblasts appear able to support the maintenance of the SC population, 
co-culture with adipocytes led to a significant decrease in the mRNA abundance of 
CD133, Nanog, and Oct4, potentially indicative of a reduction in the stem cell phenotype 
of the cells remaining in culture. 
[* p < 0.05, ** p < 0.01 compared to 21-day BM-MPC co-culture controls; data 
expressed as mean ± SEM, normalized to β-actin and expressed as fold change of 21-
day BM-MPC co-culture controls] 
[MPCs = mesenchymal progenitor cells; Oct4 = octamer-binding transcription factor 4] 
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Figure 3.11.  Ki67 stain for proliferation of BM-MPCs, adipocytes, and osteoblasts. 
 (A, C, & E)  The number of Ki67-positive cells was low among MPCs, as well as cells 
maintained under adipogenic and osteoblastogenic differentiation conditions, indicative 
of low rates of proliferation.  (B, D, & F)  Few proliferating cells under each culture 
condition can be seen under 40-fold magnification. 
[A, C, & E taken at 10x magnification; B, D, & F taken at 40x magnification] 
[MPCs = mesenchymal progenitor cells] 
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remodeling between BM-MPCs, adipocytes, and osteoblasts that may contribute to the 
cell types’ unique effects on CD133+ cells.   
Major proteins involved in the composition of the ECM and basement membrane 
were uniquely expressed between the three cell types (Figure 3.12).  In adipocytes, I 
observed higher levels of collagen 3A1, 4A1, and 6A1, while osteoblasts displayed 
reductions in the expression of collagen 1A1, 4A1, 5A1, and 6A1 (Figure 3.12 A).  FN 
was repressed in both adipocytes and osteoblasts relative to MPCs, while the FN 
inhibitor tenascin C was increasingly expressed among both adipocytes and osteoblasts 
relative to MPC controls (Figure 3.12 B).  HSPG2 (also known as perlecan) was found 
to be significantly repressed in osteoblasts relative to control MPCs (Figure 3.12 C).  
Other basement membrane component proteins were also modulated (Figure 3.12 D).  
Laminin C1, nidogen 1, and nidogen 2 were up-regulated, while laminin C2 was 
significantly down-regulated in adipocytes.  Osteoblasts displayed repression of laminin 
C1 and C2, though the expression of nidogen 1 was substantially increased.   
Genes involved in remodeling the ECM were also uniquely regulated between 
the cell types.  The majority of ADAM peptidases were down-regulated in osteoblasts, 
with significant repression of ADAMs 9, 10, 12, 15, 19, 21, and 28 relative to MPCs 
(Figure 3.13 A).  ADAMs were selectively regulated in adipocytes, with repression of 
ADAMs 9 and 19 and increased expression of ADAMs 10, 15, and 17.  Adipocytes and 
osteoblasts also displayed unique expression of MMPs (Figure 3.13 B).  In adipocytes, 
there were significant decreases in the mRNA abundance of MMPs 1, 2, 11, 14, and 16, 
and up-regulated expression of MMPs 13, 15, 17, 19, and 24.  Alternatively, osteoblasts 
displayed repression of MMPs 1, 2, 10, 11, 14, 15, 16, 17, and 24 relative to MPCs,   
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Figure 3.12.  ECM gene expression by MPCs, adipocytes, and osteoblasts. 
(A) There was selective regulation of several collagen subtypes compared to MPCs in 
adipocytes and osteoblasts, respectively.  (B) Both adipocytes and osteoblasts were 
characterized by significant repression of FN expression and up-regulation of tenascin 
C.  (C) HSPG2, also known as perlecan, was found to be significantly repressed in 
osteoblasts relative to MPC controls.  (D) Adipocytes displayed increased mRNA 
abundance of basement membrane component proteins laminin C1, nidogen 1, and 
nidogen 2, with reduced expression of laminin C2.  In osteoblasts, laminin C1 and C2 
were both down-regulated, while nidogen 1 expression was substantially increased.  
[† p < 0.1, * p < 0.05, ** p < 0.01, *** p < 0.001 compared to BM-MPC controls; data 
expressed as mean ± SEM, normalized to β-actin and expressed as fold change of BM-
MPC controls] 
[HSPG2 = heparin sulfate proteoglycan 2; MPCs = mesenchymal progenitor cells] 
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Figure 3.13.  Expression of ECM remodeling protein genes by MPCs, 
adipocytes, and osteoblasts. 
(A) Adipocytes and osteoblasts displayed unique patterns of expression of 
members of the ADAMs family of peptidases.  Adipocytes were characterized by 
up-regulation of most ADAM subtypes, while osteoblasts demonstrated 
repression of most ADAM genes.  (B) The expression of a number of MMPs were 
selectively regulated by adipocytes and osteoblasts relative to control MPCs.  (C) 
TIMPs were also differentially expressed by the three cell types, with repression 
of TIMP 2 and 3 and substantial up-regulation of TIMP 4 by both adipocytes and 
osteoblasts.  (D) Membrane-bound aminopeptidase A was also found to be up-
regulated in adipocytes and osteoblasts relative to MPCs. 
 [† p < 0.1, * p < 0.05, ** p < 0.01, *** p < 0.001 compared to BM-MPC controls; 
data expressed as mean ± SEM, normalized to β-actin and expressed as fold 
change of BM-MPC controls] 
[ADAM = a disintegrin and metalloproteinase; Aminopeptidase A = glutamyl 
aminopeptidase; MMP = matrix metalloproteinase; MPCs = mesenchymal 
progenitor cells; TIMP = tissue inhibitor of metalloproteinase] 
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while MMPs 3 and 13 were substantially up-regulated.  Tissue inhibitors of 
metalloproteinases (TIMPs) demonstrated similar patterns of expression in 
adipocytes and osteoblasts, with both cell types repressing the expression of 
TIMPs 2 and 3 and significantly up-regulating TIMP 4 in comparison with 
expression by MPCs (Figure 3.13 C).  The membrane-anchored protease 
aminopeptidase A was also observed to be increasingly expressed by both 
adipocytes and osteoblasts (Figure 3.13 D).  
 qRT-PCR was also employed to investigate changes in the expression of 
45 unique niche genes involved in cell-to-cell communication following 
adipogenic and osteogenic differentiation of BM-MPCs.  I observed significant 
differences in the expression of genes involved in the Notch signalling system, 
with up-regulation of Notch receptors 1 and 2, as well as Notch ligand JAG1 in 
osteoblasts and increased expression of DLL4 in adipocytes (Figure 3.14 A and 
B).  Integrin-α4 was the only cell adhesion molecule to be differentially regulated, 
with substantial up-regulation in osteoblasts (Figure 3.15).  The pro-angiogenic 
chemokine SDF-1 was found to be repressed by osteoblasts relative to MPC 
controls (Figure 3.16).  Adipocytes displayed significant increases in the 
expression of vascular growth factors Ang1 and Ang2, while the changes in the 
expression of either of these factors failed to reach significance in osteoblasts 
(Figure 3.17 A).  As Ang1 and Ang2 play antagonistic roles, I elected to compare   
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Figure 3.14.  Expression of Notch signalling genes in MPCs, adipocytes, 
and osteoblasts. 
(A) Notch receptors 1 and 2 were significantly up-regulated in osteoblasts.  (B) 
Notch ligands DLL4 and JAG1 were up-regulated in adipocytes and osteoblasts, 
respectively, in comparison to control MPCs.  
[† p < 0.1, ** p < 0.01, *** p < 0.001 compared to BM-MPC controls; data 
expressed as mean ± SEM, normalized to β-actin and expressed as fold change 
of BM-MPC controls] 
[DLL = delta-like ligand; JAG = Jagged; MPCs = mesenchymal progenitor cells] 
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Figure 3.15.  Cell adhesion molecule gene expression in MPCs, adipocytes, 
and osteoblasts. 
Integrin-α4 was the only gene involved of cell adherence to be differentially 
expressed between the cell types with a significant increase in expression in 
osteoblasts.  
[* p < 0.05 compared to BM-MPC controls; data expressed as mean ± SEM, 
normalized to β-actin and expressed as fold change of BM-MPC controls] 
[MPCs = mesenchymal progenitor cells; N-cadherin = neural cadherin; VCAM = 
vascular cell adhesion molecule] 
  
* 
0
5
10
15
20
25
Integrin-α4 Integrin-β1 N-Cadherin VCAM
R
e
la
ti
v
e
 m
R
N
A
 E
x
p
re
s
s
io
n
 
MPCs
Adipocytes
Osteoblasts
  
87 
 
 
 
Figure 3.16.  Expression of SDF-1 in MPCs, adipocytes, and osteoblasts. 
Expression of the pro-angiogenic factor SDF-1 was found to be significantly 
decreased in osteoblasts.  
 [* p < 0.05 compared to BM-MPC controls; data expressed as mean ± SEM, 
normalized to β-actin and expressed as fold change of BM-MPC controls] 
[MPCs = mesenchymal progenitor cells; SDF-1 = stromal cell-derived factor-1] 
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Figure 3.17.  Expression of angiopoietin genes in MPCs, adipocytes, and 
osteoblasts. 
(A) Adipocytes were characterized by significantly increased mRNA abundance 
of both Ang1 and its antagonist, Ang2, in comparison to BM-MPC control cells.  
(B) When compared as the ratio between the pro-angiogenic Ang1 and anti-
angiogenic Ang2, there was no difference relative to MPCs in adipocytes, though 
osteoblasts demonstrated a four-fold increase in this ratio.  
[* p < 0.05, ** p < 0.01 compared to BM-MPC controls; data expressed as mean 
± SEM, normalized to β-actin and expressed as fold change of BM-MPC controls] 
[MPCs = mesenchymal progenitor cells; Ang = angiopoietin] 
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the expressions of these two factors as the ratio of Ang1 relative to Ang2 (Figure 
3.17 B).  In adipocytes, this ratio was very similar to that of MPCs,  although the 
ratio approached 4.5 in osteoblasts, suggesting a much greater contribution to 
the surrounding niche by Ang1 in osteoblast-predominant culture. 
3.5 Identifying Potential Role of Ang1 & Ang2 in SC Niche 
 I was particularly intrigued by the finding in outlined in Figure 3.17, with 
increased expression of Ang1 and Ang2 in adipocytes and an increased Ang1-to-
Ang2 ratio in osteoblasts and set out to determine the effects that varying 
concentrations of Ang1 and Ang2 have on CD133-positive SCs.  To do this, 
CD133+ cells were cultured at 5,000 cells/cm2 for seven days in DMEM with 10% 
FBS containing one of six concentrations of Ang1 or Ang2 (Table 3.1).  qRT-PCR 
was then performed to quantify the expression of SC marker CD133 and EC 
marker CD31. 
 Although meaningful significance was not attained, several important 
points could be raised.  CD133 mRNA was reduced in each culture condition 
relative to 0 Ang controls, though this was not statistically significant (Figure 3.18 
A).  Ang1, which is responsible for promoting endothelial differentiation, seemed 
to increase the expression of EC marker CD31 when added to culture at 100 
ng/mL or 75 ng/mL + 25 ng/mL Ang2 (Figure 3.18 B)345.   
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Table 3.1.  Treatment conditions for Ang1-Ang2 overabundance 
experiment. 
CD133+ cells were cultured for seven days in DMEM containing the 
concentrations of Ang1 and Ang2 listed below.   
 
  
Label Ang1 Ang2 
0 Ang 0 ng/mL 0 ng/mL 
A1 100 100 ng/mL 0 ng/mL 
A1 75 / A2 25 75 ng/mL 25 ng/mL 
A1 50 / A2 50 50 ng/mL 50 ng/mL 
A1 25 / A2 75 25 ng/mL 75 ng/mL 
A2 100 0 ng/mL 100 ng/mL 
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Figure 3.18.  Expression of SC and EC markers in CD133+ cells upon Ang 
exposure. 
CD133+ cells were maintained for seven days in DMEM containing varying 
concentrations of Ang1 and Ang2 before quantification of markers of SC and EC 
phenotypes.  (A) SC marker CD133 mRNA levels  (B)  EC marker CD31 mRNA 
levels 
[Data expressed as mean ± SEM, normalized to β-actin and expressed as fold 
change of 0 Ang controls] 
[Ang = angiopoietin] 
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3.6 CD133-Positive Cell Adhesion Molecule & Receptor 
Expression 
 I conducted qRT-PCR analyses of various niche receptor and cell 
adhesion molecule genes in CD133+ cells in order to confirm the expression of 
reciprocal factors that correspond to genes in which we observed differential 
expression patterns between mesenchymal cell types.  I utilized MPCs as 
controls to compare to the relative mRNA levels in CD133+ cells.  I observed 
substantive expression of integrin-α4, along with robust expression of VE-
cadherin, which is a characteristic endothelial marker (Figure 3.19 A).  CD133+ 
cells also displayed a reduced expression of VCAM relative to BM-MPCs.  
NOTCH1 was the predominant Notch receptor protein expressed by CD133+ 
cells (Figure 3.19 B).  CXCR4, which serves as the receptor for SDF-1, was 
expressed in significantly higher levels in CD133+ cells relative to control MPCs 
(Figure 3.19 C).  I also observed robust expression of the Tie-1 and Tie-2, which 
serve as receptors in the angiopoietin signalling system (Figure 3.19 D).  These 
findings suggest the potential for the unique niche gene expression patterns of 
BM-MPCs, adipocytes, and osteoblasts to be parlayed into functional changes 
within the CD133+ cell population. 
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Figure 3.19.  Expression of cell adhesion molecules and niche receptors in 
CD133+ cells.   
qRT-PCR analyses of the expression of niche gene receptors in CD133+ cells 
were performed and compared to expression in cultured BM-MPCs. (A) mRNA 
levels of select integrins and cadherins  (B) mRNA levels of Notch receptors (C) 
mRNA levels of SDF-1 receptor CXCR4 (D) mRNA levels of Tie receptors 
involved in Ang1 and Ang2 signalling 
[† p < 0.1, * p < 0.05, ** p < 0.01 compared to BM-MPC controls; data expressed 
as mean ± SEM, normalized to β-actin and expressed as fold change of BM-
MPC controls]  
[CXCR4 = C-X-C chemokine receptor type 4; MPCs = mesenchymal progenitor 
cells; N-cadherin = neural cadherin; Tie = tyrosine kinase with immunoglobulin-
like and EGF-like domains; VCAM = vascular cell adhesion molecule; VE-
cadherin = vascular endothelial cadherin] 
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3.7 In Vivo Diabetic Model 
 Clinical variables of diabetic and control rats were recorded and reported 
in Table 3.2.  All rats receiving injections of STZ were confirmed to be diabetic 
with blood glucose measurements in excess of 25 mmol/L.  There were 
significant differences between diabetic and control animals in body weight (p < 
0.01), blood glucose levels (p < 0.01), heart weight (p < 0.1), and tibia length (p < 
0.01).   
My data confirmed an increase in marrow adipogenesis in diabetic rats, as 
demonstrated by the increased expression of adipogenic transcription factors 
C/EBP-α and C/EBP-β (Figure 3.20 A).  Although non-significant, expression of 
pro-osteoblastic factors BGLAP, Runx2, and Sp7 seemed lower in diabetic 
animals (Figure 3.20 B).  Potentially increasing the sample size may show 
significantly lower levels.  Expression of MPC marker CD105 was not altered in 
the diabetic animals.  While the putative marker of EPCs in humans, CD133 is 
not exclusive to SCs in rats.  Therefore, I elected to utilize other SC-specific 
markers: Nanog, Oct4, and Sox2.  Expression of Nanog, Oct4, and Sox2 all 
displayed slight decreases in mRNA abundance in diabetic animals, though this 
difference was not significant (Figure 3.20 D).    
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Table 3.2.  Clinical variables of control and diabetic rats used in in vivo 
model of diabetes. 
 
  
 Control Mean Diabetic Mean P-Value 
Body Weight 551.67 g 302.67 g p < 0.01 
Blood Glucose 6.87 mmol 29.2 mmol p < 0.01 
Heart Weight 1.78 g 1.03 g p < 0.1 
Tibia Length 5.57 cm 4.57 cm p < 0.01 
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Figure 3.20.  In vivo expression of adipogenic, osteogenic, MPC, and SC 
markers in marrow of diabetic rats. 
(A) Increased expression of adipogenic transcription factors were found in the 
BM of diabetic rats.  (B) The decrease in the mRNA expression of osteogenic 
markers failed to reach significance.  (C) The expression of MPC marker CD105 
was not significantly altered in the BM of diabetic rats.  (D) A non-significant 
reduction in the expression of SC markers was observed in diabetic marrow. 
[† p < 0.1; data expressed as mean ± SEM, normalized to β-actin and expressed 
as fold change relative to control rat femurs; n = 3] 
[BGLAP = bone gamma-carboxyglutamic acid-containing protein; C/EBP = 
CCAAT-enhancer-binding protein; Oct4 = octamer-binding transcription factor 4; 
Runx2 = runt-related transcription factor 2; Sox2 = sex determining region Y-box 
2] 
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Chapter 4 : Conclusions 
4 Conclusions 
4.1 Discussion 
 I have demonstrated a reduction in the mRNA expression of SC markers 
CD133, Nanog, and Oct4 following co-culture of CD133+ cells with adipocytes 
after 21 days.  I first set out to identify a suitable substrate on which to culture 
and differentiate BM-MPCs which was essential for creating the in vitro SC niche 
model and downstream experimentation.  Adipogenic differentiation has been 
shown to be hindered by FN and unaffected by collagen.  FN is believed to exert 
its anti-adipogenic effect by preventing the necessary changes in morphology 
required for development of a fibroblast-like MPC into a large, rounded 
adipocyte343.  Through the induction of differentiation of BM-MPCs on collagen 1-
coated and FN-coated plates, I was able to confirm a role for FN in delaying 
adipogenesis.  Collagen 1 did not have any significant effect on the expression of 
differentiation factors, confirming its potential as an ECM substrate in 
differentiation culture systems346.   
 I also analyzed the expression of three factors, CD133, Nanog, and Oct4, 
believed to be specific to SCs in BM-MPCs, adipocytes, and osteoblasts.  These 
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three cell types are thought to be negative for the expression of the 
aforementioned SC markers, though some reports have identified their 
expression in more differentiated cell types and MSCs347-351.  I observed no 
detectable expression of CD133 by BM-MPCs, adipocytes or osteoblasts, 
supporting its use as the ideal marker to identify SCs in mixed cultures.  The 
relative expression levels of Nanog and Oct4 were also undetectable in each of 
the three mesenchymal cell types in comparison to fresh CD133+ cells, 
supporting the use of these genes as secondary markers for the SC phenotype in 
our co-culture experiments. 
I next investigated how altering the cellular composition of the 
microenvironment affected the adherence of CD133+ cells within an in vitro co-
culture system.  EPCs have previously been shown to have poor adherence in 
culture, as well as an overall loss of CD133 expression over time, while improved 
EPC adhesion may correlate to enhanced endothelial function352-355.  My findings 
confirmed this characteristic of CD133+ cells, as co-culture with BM-MPCs or 
adipocytes led to significant reductions in the expression of CD133.  Interestingly, 
co-culture with osteoblasts led to an increase in the mRNA of SC markers Nanog 
and Oct4, with a non-significant increase in the expression of CD133 after 21 
days.  Osteoblasts are characterized by a strong production of collagen 1, which 
has been shown to enhance cell adhesion in a number of cell types356-358.  
Additionally, collagen 1 has been shown to specifically facilitate the survival and 
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proliferation of EPCs in vitro, which may contribute to the increased mRNA 
abundance of SC markers in this co-culture system after 21 days359.  
 I also explored the effects of co-culture of CD133+ cells with BM-MPCs, 
adipocytes, or osteoblasts on the survival or maintenance of these cells in an 
SC-like state.  Via a modified survival assay, I profiled how the expression of SC 
markers changed over time in co-cultures of CD133+ cells with MPCs or MPC-
derived adipocytes or osteoblasts.  Interestingly, I noted a significant reduction in 
the mRNA abundance of CD133, Nanog, and Oct4 in co-culture with adipocytes 
relative to co-culture with BM-MPCs after 21 days.  This suggests that adipocytes 
are responsible for the production of signals or cell-cell interactions that are 
detrimental to the survival and maintenance of the CD133+ cell population.  The 
reduced expression of SC markers may be the consequence of depletion of the 
SC population, a loss of an SC-like phenotype, reduced cell proliferation, or a 
combination of the above.  Unfortunately, this model is unable to differentiate 
between a reduction in overall SC marker-positive cell number and a down-
regulation of SC factors with no change in the size of the population.  Thus, my 
results, although important, are limited to describing changes to the “stemness” 
of these cells – the maintenance of these cells in an SC-like state – rather than 
CD133+ cell quantity or cellularity.   
 A potential confounding factor to my quantification of SC gene expression 
is proliferation of background cell populations.  Division of the background cells 
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would increase the expression of housekeeping genes and dilute the expression 
of genes of interest.  I anticipated minimal effect of cell proliferation in 
differentiated cell types as adipocytes and osteoblasts are typically considered to 
be post-mitotic cell types81, 99, 360, 361.  Alternatively, MPCs are a highly 
expandable and proliferative cell type362.  However, this property is believed to 
decrease in high density cultures363.  To minimize the potential for proliferation of 
background cell types to artificially decrease SC marker expression, co-culture 
cell populations were maintained at high density.  I also performed 
immunofluorescence staining of MPCs, adipocytes, and osteoblasts for the 
proliferation marker Ki67 to confirm a low rate of division in these cells.  I 
observed very few Ki67-positive cells in each of the three culture conditions.  
High seeding density and exposure to differentiation media appear to be 
sufficient to inhibit the division of MPCs.  From this stain, I can conclude that the 
changes in SC gene expression under co-culture systems were not the artefact 
of differential proliferation of background cells. 
 Particularly within the HSC niche, adipocytes are considered to play a 
pivotal role in guiding SC development364.  While some research advocates for a 
positive role for adipocytes, general consensus supports an inhibitory function for 
adipocytes on the maintenance of the HSC population365-367.  At birth, HSCs are 
found throughout the skeleton368.  During postnatal development, conversion of 
areas of red BM to adipocytic yellow marrow results in the confinement of 
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hematopoiesis to specific regions within the skeletal system, such as flat bones 
and the epiphyseal ends of long bones364.  Large, round adipocytes may 
compress walls of sinusoids to restrict blood flow, consequently transforming 
regions previously of red marrow into fatty yellow BM, which are characterized by 
a limited blood supply364, 369.  In vivo, an overabundance of adipocytes within 
diabetic BM may similarly occlude capillaries to limit the accessibility of VSCs 
and EPCs to the vasculature.  This may restrict the exposure of these cells to 
pro-vasculogenic chemotactic signals, as well as the ability of these cells to 
mobilize from the BM and enter into circulation.  As reductions in blood supply 
are not a factor in my co-culture systems, I have identified the novel potential for 
adipocyte-specific cell-cell interactions or alterations to the extracellular 
microenvironment to negatively regulate the stemness of CD133+ cells.   
 My second objective sought to quantify differential expression of niche and 
ECM-related genes between adipocytes and osteoblasts relative to control BM-
MPCs that may account for the differences in SC adherence and survival I 
observed in the first aim.  A secondary goal was also to provide the groundwork 
for future studies investigating individual changes and the contribution to SC 
dysfunction.  My results demonstrate that adipocytes are responsible for the 
creation of a distinct microenvironment, with modulated expression of factors 
known to exert influence over SC development and vasculogenesis.  
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 The ECM has recently been shown to play a critical role in governing the 
fate of SCs, through both cell interactions and mechanical forces.  Differential 
ECM production  by the stromal cells comprising the SC niche regulates SCs 
through direct physical interactions with cells, ECM-receptor signalling, and 
modified mechanical properties that allow or disallow for SC migration and 
morphological changes necessary for differentiation370, 371.  I found that 
adipogenic matrix is characterized by increased expression of most collagen 
subtypes, with significant up-regulation of collagens 3A1, 4A4, and 6A1.  This 
finding corroborates previous findings of enhanced synthesis of type 4 collagen 
following adipogenesis, though the reported expression of other collagen 
subtypes varies between studies372-380.  Notably not up-regulated however, was 
collagen 1A1, which has been shown to facilitate the in vitro survival and 
proliferation of EPCs359.  Culture of EPCs on type 1 collagen-coated growth 
surfaces has been shown to improve their proliferative and migratory 
capabilities381.  The observed up-regulation of various collagen subtypes is likely 
to contribute to an increase in the overall concentration of collagen within the 
ECM.  A 2010 study by Critser et al. determined that increasing the concentration 
of collagen in a three-dimensional matrix influenced the vasculogenic capacity of 
EPCs, resulting in a significant decrease in the number of functional EPC-derived 
vessels in a given area382.  Other investigations have confirmed that more 
malleable matrix substrates favour blood vessel formation over high density 
ECM383-385.  Thus, the increased collagen production by adipocytes may result in 
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reduced profusion of the marrow microenvironment in which VSCs and EPCs 
reside. 
 I also observed a significant decrease in the mRNA expression of most 
collagen subtypes in osteoblasts, with significant repression of collagens 1A1, 
4A4, 5A1, and 6A1.  Osteoblastic matrix has typically been characterized by 
significant expression of type 1 collagen, which comprises 90-95% of organic 
matrix within mature bone386.  This discrepancy in collagen mRNA production 
may be the result of the time point at which gene expression was assessed.  I 
induced osteoblastic differentiation over 14 days, though significant matrix 
deposition could be observed visually within one week of induction387.  After 14 
days of differentiation, the culture growth surface was fully covered with 
osteogenic matrix, which may have resulted in down-regulation of ECM-related 
genes through a negative feedback mechanism.  Pursuing a time-course 
analysis of ECM gene expression throughout the osteoblastic differentiation 
period may reveal the characteristic up-regulation of type 1 collagen typically 
seen in osteoblasts. 
 Various collagen subtypes have been reported to influence the 
differentiation of MPCs.  We and others have reported either positive or no 
effects of collagen on adipogenesis, though this finding is not unanimous388-391.  
Types 1, 2, and 3 collagens have been shown to play important roles in 
promoting the differentiation and function of osteoblasts390, 392-396.  Collagen-
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coated culture dishes also increased the adhesion, proliferation, and function of a 
differentiated osteoblastic cell line397.  The changes I observed in collagen gene 
expression in adipocytes may facilitate negative feedback to limit further 
adipogenic differentiation of MPCs by promoting osteoblastic lineage 
commitment.  
 I also observed a significant decrease in the expression of FN, coupled 
with up-regulation of its inhibitor, tenascin C, in both adipocytes and osteoblasts, 
which corroborates existing literature.  FN has previously been shown to be 
down-regulated throughout adipogenic differentiation, as the existing FN network 
becomes degraded to allow for morphological changes to cell shape377-380, 389, 398, 
399.  FN is one of the earliest matrix proteins up-regulated during bone 
development, though its expression falls significantly throughout the bone 
maturation process400, 401.  Additionally, tenascin C, the glycoprotein inhibitor of 
FN, has been shown to be up-regulated during osteogenic differentiation402, 403.   
 FN has been shown to exert significant influence over SCs and EPCs.  
Culture of EPCs on a FN substrate was found to accelerate the appearance of 
endothelial colonies relative to coating of cell growth surfaces with type 1 
collagen359.  EPCs cultured on FN also demonstrate superior adhesion in 
comparison to culture on collagen or laminin substrata, and improved migration 
over culture on laminin-coated surfaces381.  FN also accelerates the 
differentiation process of EPCs into ECs146, 404.  Thus, my observed down-
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regulation in the expression of FN in adipocytes and osteoblasts may exert a 
negative effect on EPC adhesion and function. Interestingly, advanced glycation 
of FN, as often seen diabetes, has been shown to impair EPC attachment and 
migration, as well as chemotactic targeting to sites in need of vascular repair405.   
 One study by Ballard et al. has identified a potential role for tenascin C in 
EPC homing, with EPCs preferentially incorporating into regions of tenascin C 
expression in the heart406.  This effect is further manifested as a failure for 
tenascin C-knockout mice to induce angiogenesis into cardiac allografts406.  
Tenascin C is also well-known to possess SC-modulatory effects in a number of 
other SC niches407, 408.  Tenascin C is partially responsible for the generation of a 
neural SC niche within the subventricular zone and is involved in facilitating 
neural SC development409.  Tenascin C-knockout studies reveal a role for 
tenascin C in regulating the differentiation of neural SCs and maintaining the cell 
population in an SC-like state409.  Within the BM, tenascin C is also a key factor 
in regulating hematopoiesis410.  Tenascin C-knockout mice also displayed 
reduced hematopoietic activity and HSC long-term survival, though these effects 
could be reversed with the addition of soluble tenascin C to culture410.  Although 
a definitive function for tenascin C within the VSC niche has yet to be elucidated, 
the involvement of this protein in other SC niches highlights its importance and 
pervasiveness in developmental processes.  
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 As described above, FN has previously been shown to drastically reduce 
the adipogenic capability of MPCs341, 343, 411.  FN has also been reported to 
influence osteoblastic development, accelerating the expression of genes 
involved in osteogenic adhesion, proliferation, differentiation and function412-414.  
The effects of FN on osteoblast differentiation have been shown to be mediated 
via interactions with integrins340.  Following differentiation, FN may continue to 
have an anabolic effect on bone by preventing the apoptosis of mature 
osteoblasts415.  Interestingly, although it typically serves as an inhibitor of FN, 
tenascin may also have a stimulatory effect on osteoblastic progenitor cell 
proliferation, differentiation, and osteogenic function416.  
 I observed selective regulation of other genes involved in the formation of 
the basement membrane between BM-MPCs, adipocytes, and osteoblasts.  I 
found HSPG2 to be expressed by adipocytes, which confirms existing literature, 
while I report a novel finding in that HSPG2 is significantly down-regulated in 
osteoblasts378, 417.  HSPG2 has been shown to demonstrate strong anti-adhesive 
properties, which may contribute to our observed differences in CD133+ cell 
adherence in co-culture with adipocytes and osteoblasts418.  Although there is no 
known function for HSPG2 in regulating VSCs or EPCs within the BM, HSPG2 
may bind to VEGFR of ECs to stimulate angiogenesis419, 420.  Within the marrow, 
HSPG2 has dual effects on MPC differentiation, with exogenous HSPG2 
promoting osteoblastic differentiation while inhibiting adipogenesis421.  Taking 
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into account my results, this suggests the possibility of a negative feedback 
mechanism between HSPG2 expression and MPC differentiation.   
 I have also identified laminin as being uniquely regulated between the 
three mesenchymal cell types.  In adipocytes, I observed up-regulation of laminin 
C1, with repression of laminin C2, as has been previously described399, 422.  
Adipocytes have been characterized as having a distinct expression of laminin 
proteins, with predominant expression of the laminin-8 (α4β1γ1) isoform, which is 
in agreement with my finding of increased expression of the laminin C1 gene373, 
422.  Osteoblasts, however, were characterized by significant down-regulation of 
both laminin C1 and laminin C2.  Laminin is abundant in the early osteoid matrix 
produced by developing osteoblasts, though this expression is later supplanted 
by collagen, osteocalcin, bone sialoprotein, and others386.  Laminin is known to 
exert a significant influence over the differentiation of MPCs by accelerating the 
rate of osteoblastogenesis412, 423.  Specifically, laminin-5 (α3Aβ3γ2) increases the 
expression of osteogenic genes via a focal adhesion kinase (FAK) and ERK-
dependent mechanism424-427.  The reduced expression of laminin C2 by 
adipocytes and osteoblasts observed in my study may contribute to an inhibitory 
mechanism to suppress further osteoblastogenesis.  
 In my investigation, up-regulation of nidogen-1, also known as entactin, 
was observed in both osteoblastic and adipocytic cultures, although nidogen-2 
was increasingly expressed only by adipocytes.  Previous studies have also 
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identified nidogen-1 and nidogen-2 as components of the adipocytic secretome, 
which become up-regulated during or following adipogenesis373, 379, 428, 429.  One 
study has shown decreased expression of nidogen-2 in osteoblasts, though they 
also observed repression of the nidogen-1 gene430.  A critical role for nidogen-1 
has been identified in promoting adhesion of a variety of cell types to the 
matrix431-433.  Additionally, nidogen-laminin complexes have been found to 
possess both stimulatory and inhibitory actions on angiogenesis434.  While 
concentrations between 30 and 300 μg of laminin-nidogen complexes per mL 
promoted vessel development and elongation, a concentration of 3,000 μg/mL 
proved inhibitory to vasculogenesis, providing credence to the notion that the 
basement membrane is able to dynamically regulate vessel development434.   
 My profiling studies also revealed significant cell type-dependent 
differences in the expression of matrix remodeling proteins.  I identified 
repression of ADAM-9 and -19 and up-regulation of ADAM-10, -15, and -17 in 
adipocytes.  Early adipogenesis has been characterized by a transient increase 
in the expression of ADAM-12, which promotes matrix reorganization to 
accommodate changing cell morphology, though my study reports a novel 
change in ADAM expression by fully developed in vitro adipocytes435, 436.  In 
osteoblasts, I noted a repression of most ADAMs, with significant down-
regulation of ADAM-9, -10, -12, -15, -19, -21, and -28.  In mice, knockout of the 
ADAM-15 gene resulted in increased activity of osteoblasts, ultimately leading to 
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enhanced bone mass437.  This role for ADAM-15 in skeletal homeostasis 
corresponds with my observed regulation of the gene following adipogenic and 
osteogenic differentiation.  
 Substantial differences in the expression of MMPs were also observed, 
with repression of MMP-1, -2, -10, -11, -14, -15, -16, -17, and -24 and up-
regulation of MMP-3 and -13 in osteoblasts.  Down-regulation of MMPs has 
previously been demonstrated following osteogenesis of BM-MPCs438.  In 
adipocytes, I observed down-regulation of MMP-1, -2, -11, -14, and -16 and 
increased expression of MMP-13, -15, -17, -19, and -24.  Inhibitors of MMPs, or 
TIMPs, were also selectively regulated following differentiation, with repression of 
TIMP-2 and -3 and induction of TIMP-4 in both adipocytes and osteoblasts.  A 
prior study observed significant induction of MMP-2 in the early stage of 
adipogenesis, though its expression returned to a low level after six days of 
differentiation439.  Also observed was a progressive increase in the expression of 
MMP-19 throughout the course of differentiation, aligning with the results attained 
in my study439.  As with ADAMs, the temporal activation of specific MMPs is 
necessary for the differentiation of MPCs into mature adipocytes and thus, the 
observed changes in the expression of MMPs and TIMPs by adipocytes and 
osteoblasts may have feedback effects on MPC differentiation439-441.  
Additionally, though little is known about the process, MMP and ADAM 
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metalloproteinases are believed to be involved in the mobilization of EPCs from 
the BM166, 442.   
 Aminopeptidase A is a transmembrane peptidase involved in the cleavage 
of glutamic and aspartic amino acid residues from the N-terminus of various 
proteins.  I observed up-regulation of aminopeptidase A in both adipocytes and 
osteoblasts in comparison to BM-MPCs.  Another study has previously identified 
expression of aminopeptidase A in mature osteoblasts, but I believe my study is 
the first to characterize the induction of this peptidase following the adipogenic or 
osteogenic differentiation of MPCs443.  Aminopeptidase A has been reported to 
possess a role in ischemia-induced angiogenesis, promoting migration and 
proliferation of ECs444.  Knockout of aminopeptidase A impairs angiogenesis in a 
hind limb ischemia model, through a reduction in the stability of HIF-1α445.   
 I also investigated the changes in expression of a variety of niche genes 
between BM-MPCs and BM-MPC-derived adipocytes and osteoblasts.  I first 
investigated the expression of components that comprise the Notch signalling 
system that plays integral roles in directing SC fate and developmental 
processes.  In osteoblasts, I observed significant up-regulation of Notch 
receptors 1 and 2, along with increased expression of the Notch ligand JAG1.  
Alternatively, adipocytes were characterized by induction of Notch ligand DLL4.  
The Notch signalling pathway is critically involved in governing the development 
of a number of SC types446-448.  Within the BM, Notch has been implicated in 
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preventing osteoblastic differentiation to preserve the MPC population, though 
some studies contradict this notion449-452.  A stimulatory role for the Notch 
pathway has been identified in adipogenesis, though again, this finding is not 
unanimous449, 451, 453, 454.   
In a profile of niche gene expression in CD133-positive SCs, I identified 
NOTCH1 as the predominant receptor within the Notch signalling system in these 
cells.  The expression of Notch signalling components in EPCs suggests that the 
observed changes in Notch gene expression by adipocytes and osteoblasts may 
be parlayed into functional differences in the angiogenic capacity of EPCs.  
Notch signalling in EPCs has previously been shown to promote the proliferation 
of these cells and their mobilization and migration towards sites of vascular 
injury455, 456.  Notch also regulates the in vitro adhesion of EPCs to the ECM by 
modulating integrin expression, and inhibition of this pathway impairs the ability 
of these cells to form tube-like structures457.  In vivo activation of Notch signalling 
increased the angiogenic capacity of EPCs to improve wound healing in a mouse 
model457.  
The effects of changes in the abundance of Notch ligands on EPC survival 
and function have also been investigated.  Conditional knockout of JAG1 in mice 
was associated with a reduction in the expression of EC markers within the BM, 
limited colony-formation by EPCs, as well as impaired EPC proliferation, 
migration, survival, and vasculogenic ability, while knockout of DLL1 had no 
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effect458.  Overexpression of JAG1 by stromal cells in a co-culture system was 
able to counter the deficits in EPC differentiation and function seen in the murine 
model458.  In ECs, JAG1 has been shown to antagonize the interaction between 
DLL4 and Notch, which has anti-angiogenic effects on vessel sprouting459-462.  
My findings of increased JAG1 in osteoblasts and repression of DLL4 in 
adipocytes provide a possible mechanism underlying the EPC impairment 
observed in diabetic BM adipogenesis.  
I observed no significant changes in the expression of genes involved in 
mediating cell-cell and cell-ECM interactions between the three cell types, with 
the exception of integrin-α4, which was significantly up-regulated in osteoblasts.  
In contrast to my results of increased integrin-α4 expression in osteoblasts, one 
study that profiled gene expression throughout osteoblastic differentiation failed 
to observe expression of integrin-α4 at any time points463.  This study made use 
of the murine MC3T3-E1 pre-osteoblast cell line, which may not be applicable to 
my model of human BM-MPC differentiation.  My gene expression profiling of 
CD133+ cells revealed that one of integrin-α4’s binding partners, VCAM, was 
expressed at a low level by these cells.  This may still be sufficient to mediate 
binding between CD133+ cells and nearby stromal cells, but this requires further 
investigation.  The observed increase in the expression of integrin-α4 by 
osteoblasts may have contributed to the enhanced SC adhesion in osteoblastic 
co-culture (data from first objective).   
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In my profiling of CD133+ cells niche gene expression, I noted that 
integrin-α4 was expressed in this cell type.  This corresponds with existing 
literature, as integrin-α4β1 has been identified as a key regulator of EPC 
adhesion and mobilization within the BM.  In vivo inhibition of integrin-α4 resulted 
in an increased propensity of EPCs to mobilize from the BM and enter into 
circulation, demonstrating the importance of this molecule in regulating SC 
adhesion464.  Integrin-α4β1 has also been found to play a role in the homing of 
EPCs from the BM to areas of neovascularization, though it may be redundant in 
its function464, 465.  At sites of acute lung injury, integrin-α4β1 expression by BM-
derived EPCs has been implicated in promoting vessel sprouting and preventing 
vascular injury, demonstrating roles for integrin-α4β1 throughout the angiogenic 
process466. 
In osteoblastic cells, I observed a significant reduction in the expression of 
SDF-1, which binds to its receptor, CXCR4, to facilitate chemotaxis of 
lymphocytes during embryogenesis and EPCs during postnatal life.  SDF-1 binds 
to CXCR4 to induce the concentration-dependent migration of EPCs via 
activation of a pathway involving PI3K, PKB, and eNOS467.  During development, 
SDF-1 is expressed early in osteoblast differentiation and is believed to act as a 
homing agent to localize SCs to the marrow468.  High expression of SDF-1 has 
been identified in immature osteoblasts and osteosarcoma cell lines, though its 
regulation in mature human osteoblasts is not conclusive469.  My results indicated 
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that CXCR4 was expressed very highly by CD133+ cells, relative to its limited 
expression in BM-MPCs.  I believe that the reduced expression of SDF-1 by 
osteoblasts may make this chemotactic gradient more detectable to EPCs in the 
BM, allowing for enhanced mobilization and migration towards sites of vascular 
injury in response to hypoxia-induced SDF-1.    
SDF-1-CXCR4-induced EPC activation has previously been shown to be 
disrupted in diabetes.  Hyperglycemia-treated EPCs display reduced expression 
of CXCR4 and suppression of the PI3K/PKB/eNOS axis known to mediate EPC 
migration470.  This finding has been confirmed in diabetic patients, who have a 
reduced number of CXCR4-positive cells in circulation and whose EPCs exhibit 
lower CXCR4 expression than health controls470, 471.  Diabetic mice display a 
reduced plasma concentration of SDF-1, as well as number of CXCR4-positive 
cells in circulation472.  Overexpression of CXCR4 in EPCs has been shown to 
enhance the colony forming ability of these cells, prevent EPC dysfunction and 
apoptosis in response to hyperglycemia, and attenuate ischemic damage in a 
model of cerebral infarction472.   
I also investigated the potential for differential regulation of vascular 
growth factors Ang1 and Ang2 between BM-MPCs, adipocytes, and osteoblasts.  
I report the novel finding that both Ang1 and Ang2 were up-regulated over 10-fold 
in adipocytes relative to MPCs, though no significant change was observed in 
osteoblasts.  Ang1 and Ang2 both serve as ligands for Tie-1 and 2 receptors, 
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which I have shown are expressed in CD133+ cells.  Tie-2 is particularly 
important in angiogenesis, as well as EC proliferation and maintenance of 
vascular networks473.  Alternatively, Tie-1 heterodimerizes with Tie-2 to facilitate 
Tie-2 signalling, and is also important in establishing vessel integrity473, 474.  
When bound to Tie-2, Ang1 is pro-angiogenic and is involved in vessel 
development, while binding of Ang2 acts as an antagonist to Ang1, disrupting the 
formation of blood vessels and inducing EC apoptosis475-479.   
Because Ang1 and Ang2 serve as antagonists to one another, I believed it 
was prudent to investigate the expression of these factors as the ratio between 
them, rather than their individual expression.  Although both Ang1 and Ang2 
were up-regulated in adipocytes, the ratio of Ang1 relative to Ang2 remained 
similar to that of MPCs.  Alternatively, osteoblasts displayed a four-fold increase 
in the Ang1/Ang2 ratio in comparison to control MPCs, suggesting that 
osteoblasts may preferentially stimulate BM-EPC survival and function.  My 
finding was in agreement with previous work citing a strong preference for Ang1 
production in osteoblasts480, 481.  Additionally, a study investigating the effects of 
Ang1 in the HSC niche found that Ang1 was able to heighten SC adhesion to 
osteoblasts, which may contribute to the increased adherence of CD133+ cells 
with osteoblasts in my co-culture model330.  
Murine models of diabetes have revealed significant involvement of the 
angiopoietin signalling system on perpetuating vascular injury.  Increased 
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expression of Ang2 has been found in the cardiac tissue of diabetic mice relative 
to non-diabetic control animals345.  This study by Tuo et al. also reported 
increased vascular damage and tissue apoptosis following myocardial infarction 
in diabetic mice relative to healthy controls345.  This was reversed through 
overexpression of Ang1, and exacerbated by overexpression of Ang2345.  In 
humans, the plasma concentrations of Ang2 are elevated in diabetic subjects 
relative to healthy controls, though there was no difference in Ang1 levels482.  In 
relation to diabetic complications, Ang2 levels have been found to be significantly 
elevated in some forms of diabetic retinopathy the vascular changes to the retina 
can be reversed in a rat model through local or systemic overabundance of 
Ang1483-485.   
Although angiopoietins are known to be critically involved in mediating 
angiogenesis and dysfunction in ECs, comparatively little is known about the 
specific effects of Ang1 and Ang2 on endothelial progenitors.  Ang1 has been 
shown to promote the migration of early endothelial outgrowth cells (a subclass 
of EPCs) and improve response to ischemia486.  Ang1 overexpression has also 
been associated with enhanced VSC differentiation into EPCs within the BM, 
though reports of its effects on the mobilization of EPCs are divided345, 487-491.   
I investigated how modulating the balance between Ang1 and Ang2 
abundance influences the stemness and endothelial properties of CD133+ cells, 
though the results failed to reach significance.  The lack of significance attained 
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in this experiment may be attributed to the concentrations of angiopoietins I used 
in the studies.  In healthy human controls, Ang1 and Ang2 concentrations are 
usually both below 10 ng/mL (range of mean concentrations for Ang1: 1-8 ng/mL; 
range of mean concentrations for Ang2: (1.5-5 ng/mL), although these values 
may be elevated in some disease states, including diabetes492-496.  In vivo animal 
models using an adenovirus to overexpress Ang1 result in maximal Ang1 plasma 
levels of 74.1 ng/mL, though this concentration may actually reduce EPC 
mobilization487, 491.  In vitro studies on ECs and EPCs however, have generally 
used Ang1 and Ang2 concentrations much greater than those seen in a 
physiological setting.  These studies have variously used exogenous Ang1 and 
Ang2 concentrations ranging from 0.1-1,000 ng/mL497-502.  While the majority of 
these investigations have focused on the upper ends of this spectrum, lower 
concentrations of Ang1 (≤ 50 ng/mL) may be capable of stimulating EC 
migration, vascular sprouting, and survival497-499.  I elected to utilize moderate 
angiopoietin concentrations closer to physiologically relevant levels than most 
published literature.  It is possible that extreme concentrations of angiopoietins 
may be required in order to induce substantive biological changes in EPCs. 
I next aimed to confirm my in vitro findings in an in vivo model of diabetes.  
As expected, there was an up-regulation of the C/EBP family of adipogenic 
transcription factors in diabetic animals indicative of enhanced marrow 
adipogenesis.  Although non-significant, the expression of osteoblastic markers 
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BGLAP, Runx2, and Sp7 appeared to be somewhat lower than that of controls (p 
= 0.124, 0.164, 0.297, respectively; n=3).  The induction of adipogenesis and 
inhibition of osteoblastogenesis are commonly observed in diabetic models335, 338, 
503.  The expression of MPC marker CD105, also known as endoglin, in rat BM 
was not significantly altered by diabetes.  In type 1 diabetes, increased BM 
adipogenesis is accompanied by a reciprocal decrease in osteogenesis, with 
minimal change to the size of the progenitor cell population.  The effect of 
hyperglycemia on BM-MPC populations is unclear, with reports of contrasting 
effects on differentiation, proliferation, and survival183, 257, 504, 505.  Although the 
finding was not statistically significant, the expression of SC markers Nanog, 
Oct4, and Sox2 did appear to be slightly reduced in the diabetic BM, which was 
to be expected given the known deleterious effects of diabetes.  
Although the majority of my in vivo results failed to breach the desired 
level of significance, the finding of increased marrow adipogenesis is in concert 
with existing literature.  A possible explanation for the lack of significance 
attained is the relatively short duration of diabetes used in the model.  Following 
injections of STZ and confirmation of elevated blood glucose concentrations, rats 
were maintained for four weeks before being euthanized.  Four weeks has 
proven to be sufficient time to induce cellular and morphological changes to 
skeletal composition in other rodent models of type 1 diabetes335-338.  A number 
of other studies have observed considerably longer disease durations before 
  
121 
 
 
analyzing changes to the BM506-508.  My four week time point may not have 
allowed sufficient time for increased BM adipogenesis to fully interfere with the 
proliferation, differentiation, and migration of BM-resident VSCs and EPCs.  
Performing a time course study of the progressive changes in diabetic BM may 
provide more definitive insight into the pathological modifications occurring within 
the marrow.   
4.2 Limitations 
In my exploration of the effects of MPCs, adipocytes, and osteoblasts on 
the survival and adherence of CD133+ SCs, I assessed the mRNA expression of 
three SC markers – CD133, Nanog, and Oct4 – via qPCR.  I utilized the levels of 
these three genes as a surrogate for the “stemness” of the cells remaining in 
culture – a composite attribute incorporating both SC quantity and SC gene 
expression.  In order to differentiate between these two characteristics, flow 
cytometry may be employed in the future to quantify the adherent and surviving 
cells in my in vitro co-culture systems.  
 The published literature regarding the expression of specific niche and 
ECM genes in adipocytes and osteoblasts is widely varied.  Discordance 
between my results and prior findings and within existing studies may be the 
consequence of different starting cell populations.  I made use of BM-derived 
MPCs and BM-MPC-derived adipocytes and osteoblasts to identify unique gene 
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expression patterns between the three cell types.  Other studies have utilized a 
variety of cell types in their investigations that may not share similar gene 
expression profiles to my cell populations.  Murine pre-adipocyte cell lines 3T3-
L1 and 3T3-F442A are most commonly used in the study of adipocytes and 
adipogenesis, though interspecies differences may exist between these cell lines 
and human BM-MPCs91, 509.  Similarly, the MC3T3 cell line is commonly used in 
studies of osteogenesis and osteoblast function, though it represents a mouse-
derived osteoblast precursor cell line rather than multi-potential precursor cells.  
Other studies use the murine mesenchymal precursor cell line C3H10T1/2 that 
better resemble MPCs.  These cells display equivalent osteoblastic development 
as BM-MPCs, though their capacity for adipogenesis is severely limited, with only 
10% of C3H10T1/2 cells undergoing adipogenic differentiation510.  The 
interspecies differences that exist between commonly used murine cell lines and 
human BM-MPCs used in my studies complicate the comparisons that can be 
made between these studies.   
Additionally, the culture of isolated cell types on plastic culture dishes fails 
to recapitulate the complexity of the BM that exists in vivo.  My co-culture 
experiment served as a simplistic example of the effects of excessive 
adipogenesis on CD133+ cells, but the true BM SC niche would be comprised of 
a mixture of MPCs, adipocytes, osteoblasts, HSCs, ECs, pericytes, and 
fibroblasts.  Similarly, the gene expression profiles for adipocytes, osteoblasts, 
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and MPCs is intimately linked to paracrine and cell-cell signalling from the 
various cell types within the BM, which my model fails to take into account.  Also, 
the culture of cells on collagen-coated plastic culture dishes eliminates many of 
the cellular interactions with the ECM, which may influence gene expression and 
SC phenotype.  
 It would be advantageous to confirm the findings of augmented gene 
expression in diabetic human marrow specimens, though this may not provide 
relevant results.  Over 85% of individuals with diagnosed diabetes report 
controlling their disease with insulin or other anti-hyperglycemic medication511.  
While these medications are invaluable in preventing severe diabetic 
complications, many common diabetic therapies also induce significant changes 
to the composition of the BM, particularly when used chronically.  Insulin and 
TZDs are notorious for enhancing BM adipogenesis, while metformin may 
increase bone density, so the use of these medications by diabetic subjects 
would interfere any results we may find.  The difficulty involved in identifying and 
recruiting subjects with un-medicated disease of sufficient duration and severity 
to induce skeletal changes hinders our ability to confirm these findings in human 
subjects.  
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4.3 Future Directions 
4.3.1 Confirming Gene and Protein Expression throughout 
Differentiation 
 The majority of my findings were derived by qPCR, which solely takes into 
account the mRNA abundance of target genes.  PCR limits us to detecting 
differential rates of transcription, without acknowledging changes in expression 
that occur post-transcriptionally or at the protein level.  Thus, an important next 
step would be to confirm whether the findings of augmented gene expression 
bear out in protein expression through quantitative western blot analyses.  It 
would also be beneficial to perform a time course experiment reporting 
alterations in both gene and protein expression throughout the adipogenic and 
osteoblastic differentiation processes and the life cycle of these cells in order to 
definitively establish the contributions of each cell type to the BM SC niche.  
4.3.2 Effects of Identified Target Genes on CD133-Positive Cells 
Many of the genes we identified as being differentially regulated between 
adipocytes, osteoblasts, and MPCs are known to have effects on EPCs.  
Culturing CD133+ cells in conditioned media from MPCs, adipocytes, and 
osteoblasts could help to distinguish between the effects of soluble niche factors 
and cell-cell interactions, such as the Notch signalling pathway.  The next step in 
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this research project should investigate specifically how each of these factors 
concentration-dependently influences proliferation, differentiation, migration, and 
survival in a population of CD133+ cells.  I have started this process through 
investigation of how altering the Ang1-to-Ang2 ratio affects the expression of SC 
and EC markers.  Through a combination of overabundance, overexpression, 
knockout, and inhibition experiments, we could identify how the changes in gene 
expression in adipocytes and osteoblasts directly affect VSCs.  
4.3.3 Hindlimb Ischemia Model with Altered BM Composition 
My results indicate that adipocytes may negatively impact the adhesion 
and survival of CD133+ cells.  It would be interesting to evaluate how enhanced 
marrow adipogenesis affects EPCs in vivo.  In this model, animals would be 
subjected to treatment with a variety of substances known to affect MPC 
differentiation into adipocytes and osteoblasts.  These substances could include 
bisphenol A diglycidyl ether (BADGE; adipogenic inducer), rosiglitazone 
(adipogenic inducer and osteoblastogenic inhibitor), GW9662 (adipogenic 
inhibitor), or oncostatin M (osteoblastogenesis inducer and adipogenic 
inhibitor)512-515.  Hindlimb ischemia could then be induced in these animals and 
successful reperfusion monitored.  Angiogenic ability under distinct marrow 
compositions could be contrasted with that of diabetic animals, as diabetes has 
consistently been shown to impair vascular recovery using this model179, 516, 517.  
This experiment would be of use in conclusively ascertaining the specific 
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contribution of marrow adipogenesis to diabetic VSC and EPC dysfunction, 
rather than other pathological aspects of the diabetic state such as 
hyperglycemia and hyperlipidemia.  
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